

A clinical evaluation of the International Lymphoma Study Group
non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma

Blood

89, 3909-18

Citation Report

#	ARTICLE	IF	CITATIONS
1	A New Approach to Non-Hodgkin's Lymphoma.. Internal Medicine, 2000, 39, 197-208.	0.3	11
2	Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 2000, 403, 503-511.	13.7	8,977
3	Practical Utility of the Revised European-American Classification of Lymphoid Neoplasms for Japanese Non-Hodgkin's Lymphomas. Japanese Journal of Cancer Research, 2000, 91, 351-360.	1.7	20
4	New developments in lymphoma clinical trials. Current Oncology Reports, 2000, 2, 154-156.	1.8	0
5	Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma. Medical Oncology, 2000, 17, 225-228.	1.2	17
6	Expression of c-Myc and p53 Correlates With Clinical Outcome in Diffuse Large B-Cell Lymphomas. American Journal of Clinical Pathology, 2000, 113, 512-518.	0.4	55
7	Secondary ocular involvement in systemic B-cell lymphocytic leukemia. Ophthalmology, 2001, 108, 1289-1295.	2.5	29
8	Radiation therapy for malignant lymphoma: enduring importance in the era of systemic therapy. Biomedicine and Pharmacotherapy, 2001, 55, 516-518.	2.5	0
9	Anaplastic Large Cell Lymphoma: The Shifting Sands of Diagnostic Hematopathology. Modern Pathology, 2001, 14, 219-228.	2.9	174
10	T-cell lymphoma. , 2001, , 215-232.		0
11	MALT Type Lymphoma in the Base of the Tongue.. Practica Otologica, 2001, 94, 611-616.	0.0	1
14	Successful Treatment With a Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab) for a Patient With Relapsed Mantle Cell Lymphoma Who Developed a Human Anti-Chimeric Antibody. International Journal of Hematology, 2001, 74, 70-75.	0.7	39
15	Extranodal mantle cell lymphoma mimicking marginal zone cell lymphoma. Histopathology, 2001, 39, 561-565.	1.6	14
16	Rituximab (Mabthera TM , Rituxan TM) in Patients with Recurrent Indolent Lymphoma. Medical Oncology, 2001, 18, 141-148.	1.2	24
17	Peripheral T-Cell Lymphoma with Aberrant Expression of CD79a and CD20: A Diagnostic Pitfall. Modern Pathology, 2001, 14, 105-110.	2.9	126
18	Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Therapy, 2001, 8, 378-387.	2.2	31
19	Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia. American Journal of Clinical Pathology, 2001, 116, 799-801.	0.4	33
20	Low Expression of p27 Protein Combined with Altered p53 and Rb/p16 Expression Status Is Associated with Increased Expression of Cyclin A and Cyclin B1 in Diffuse Large B-Cell Lymphomas. Modern Pathology, 2001, 14, 1105-1113.	2.9	41

#	ARTICLE	IF	CITATIONS
21	An unusual Fc receptor-related protein expressed in human centroblasts. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3776-3781.	3.3	47
22	Canine T-cell Lymphomas: A Morphological, Immunological, and Clinical Study of 46 New Cases. Veterinary Pathology, 2002, 39, 92-109.	0.8	151
23	Inhibition of Fas-mediated Apoptosis by Antigen: Implications for Lymphomagenesis. Autoimmunity, 2002, 35, 283-289.	1.2	10
24	Centroblastic and Centroblastic/Centrocytic Lymphoma Associated with a Prominent Epithelioid Granulomatous Response: a Clinicopathologic Study of 50 Cases. Modern Pathology, 2002, 15, 750-758.	2.9	11
25	Multicolor-FICTION. American Journal of Pathology, 2002, 161, 413-420.	1.9	81
26	The Distinction between Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma with c-myc Rearrangement. Modern Pathology, 2002, 15, 771-776.	2.9	82
27	Treatment of Aggressive Non-Hodgkin's Lymphoma with Chemotherapy in Combination with Filgrastim. Drugs, 2002, 62, 33-46.	4.9	5
28	Primary thyroid lymphoma: Can the diagnosis be made solely by fine-needle aspiration?. Annals of Surgical Oncology, 2002, 9, 298-302.	0.7	91
29	Follicular Lymphoma in Osaka, Japan: Histological Features and Chronological Change. International Journal of Hematology, 2002, 76, 333-337.	0.7	9
30	ziPeripheral T-cell lymphoma. Current Oncology Reports, 2002, 4, 434-442.	1.8	10
31	Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Medicine, 2002, 8, 68-74.	15.2	2,217
32	Recurrent mantle cell lymphoma after allogeneic bone marrow transplantation presenting as isolated rectal mass. Digestive Diseases and Sciences, 2003, 48, 1024-1026.	1.1	1
33	Mantle cell lymphoma: improved diagnostics using a combined approach of immunohistochemistry and identification of t(11;14)(q13;q32) by polymerase chain reaction and fluorescence in situ hybridization. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 442, 538-547.	1.4	20
34	Diffuse Large B-Cell Lymphoma: Insights Gained from Gene Expression Profiling. International Journal of Hematology, 2003, 77, 321-329.	0.7	12
35	The classification of lymphomas: a new beginning or the end of an era?. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, S13-S18.	3.3	4
36	Therapy of non-Hodgkin's lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, S28-S36.	3.3	32
37	Is t(14;18)(q32;q21) a constant finding in follicular lymphoma? An interphase FISH study on 63 patients. Leukemia, 2003, 17, 255-259.	3.3	54
38	Prognostic value of GST- π expression in diffuse large B-cell lymphomas. Leukemia, 2003, 17, 972-977.	3.3	25

#	ARTICLE	IF	CITATIONS
39	Current trends in large cell lymphoma. <i>Leukemia</i> , 2003, 17, 1948-1960.	3.3	50
40	Heterogeneous copy numbers of API2-MALT1 chimeric transcripts in mucosa-associated lymphoid tissue lymphoma. <i>Leukemia</i> , 2003, 17, 2508-2512.	3.3	9
41	Catalyzed Signal Amplification for Cyclin D1 Detection in Mantle Cell Lymphoma. <i>Modern Pathology</i> , 2003, 16, 161-165.	2.9	10
42	¹⁸ F-fluoro-deoxy-glucose positron emission tomography (¹⁸ F-FDG-PET) for assessment of enteropathy-type T cell lymphoma. <i>Gut</i> , 2003, 52, 347-351.	6.1	75
43	Marginal Zone B-Cell Lymphoma in Children and Young Adults. <i>American Journal of Surgical Pathology</i> , 2003, 27, 522-531.	2.1	157
44	Bone Marrow is Involved in Less than 10% of Patients with Nasal-Type NK/T Cell Lymphoma at Initial Diagnosis. <i>Journal of Korean Medical Science</i> , 2004, 19, 229.	1.1	12
45	A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein. <i>British Journal of Cancer</i> , 2004, 91, 141-149.	2.9	34
46	Nuclear structure in cancer cells. <i>Nature Reviews Cancer</i> , 2004, 4, 677-687.	12.8	913
47	Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2004, 34, 43-49.	1.3	43
48	Stem cell transplantation in follicular lymphoma: progress at last?. <i>Bone Marrow Transplantation</i> , 2004, 34, 929-938.	1.3	20
49	Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. <i>Leukemia</i> , 2004, 18, 589-596.	3.3	91
50	Topoisomerase III α as a prognostic factor in mantle cell lymphoma. <i>Leukemia</i> , 2004, 18, 1347-1349.	3.3	10
51	Recommendations for the reporting of lymphoid neoplasms: A report from the Association of Directors of Anatomic and Surgical Pathology. <i>Modern Pathology</i> , 2004, 17, 131-135.	2.9	28
52	Integrating Monoclonal Antibodies into the Management of Mantle Cell Lymphoma. <i>Seminars in Oncology</i> , 2004, 31, 2-6.	0.8	11
53	t(11;18)-Bearing Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Responding to Cladribine. <i>International Journal of Hematology</i> , 2004, 80, 70-74.	0.7	1
54	Primary Mediastinal Large B-Cell Lymphoma: A Single-Institution Clinical Study in Japan. <i>International Journal of Hematology</i> , 2004, 79, 465-471.	0.7	11
55	Treatment of Indolent Non-Hodgkin's Lymphoma with Cladribine as Single-Agent Therapy and in Combination with Mitoxantrone. <i>International Journal of Hematology</i> , 2004, 79, 311-321.	0.7	13
56	Nuclear Factor 3B Activation and Antiapoptosis in Mucosa-Associated Lymphoid Tissue Lymphoma. <i>International Journal of Hematology</i> , 2004, 80, 215-223.	0.7	10

#	ARTICLE	IF	CITATIONS
57	Molecular Signatures of Lymphoma. <i>International Journal of Hematology</i> , 2004, 80, 401-409.	0.7	13
58	CASE REPORT: Unusual Presentation and Diagnosis of Extraintestinal Follicular Lymphoma. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1513-1517.	1.1	1
59	Nodal peripheral T-cell lymphomas and, in particular, their lymphoepithelioid (Lennert's) variant are often derived from CD8+ cytotoxic T-cells. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 445, 334-343.	1.4	88
60	MALT Lymphoma in Children: Case Report and Review of the Literature. <i>Pediatric and Developmental Pathology</i> , 2004, 7, 407-413.	0.5	45
62	18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) does not visualize follicular lymphoma of the duodenum. <i>Annals of Hematology</i> , 2004, 83, 276-278.	0.8	29
63	Building an Outcome Predictor Model for Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2004, 164, 613-622.	1.9	87
64	BCL2 Translocation Defines a Unique Tumor Subset within the Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2004, 165, 159-166.	1.9	262
65	Cytogenetic Alterations Affecting BCL6 Are Predominantly Found in Follicular Lymphomas Grade 3B with a Diffuse Large B-Cell Component. <i>American Journal of Pathology</i> , 2004, 165, 481-490.	1.9	119
66	MRI Evaluation of Mucosa-Associated Lymphoid Tissue Lymphoma of the Lacrimal Glands. <i>The Neuroradiology Journal</i> , 2004, 17, 549-554.	0.1	0
68	Mantle Cell Lymphoma Presenting with Paraproteinemia. <i>Medical Oncology</i> , 2005, 22, 319-324.	1.2	6
69	CD5 + Diffuse Large B-Cell Lymphoma Consists of Germline Cases and Hypermutated Cases in the Immunoglobulin Heavy Chain Gene Variable Region. <i>International Journal of Hematology</i> , 2005, 81, 58-61.	0.7	4
70	Complete and Durable Remission of Refractory Mantle Cell Lymphoma with Repeated Rituximab Monotherapy. <i>International Journal of Hematology</i> , 2005, 81, 319-322.	0.7	3
71	Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. <i>Leukemia</i> , 2005, 19, 945-952.	3.3	53
72	Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances. <i>Leukemia</i> , 2005, 19, 1058-1063.	3.3	85
73	A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. <i>Leukemia</i> , 2005, 19, 1459-1465.	3.3	58
74	Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. <i>Modern Pathology</i> , 2005, 18, 1377-1384.	2.9	115
75	Molecular epidemiology of follicular lymphoma in Chinese: relationship with bcl-2/IgH translocation and bcl-6 397G/C polymorphism. <i>Annals of Hematology</i> , 2005, 84, 506-509.	0.8	3
76	Anti-apoptotic action of API2-MALT1 fusion protein involved in t(11;18)(q21;q21) MALT lymphoma. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2005, 10, 25-34.	2.2	30

#	ARTICLE	IF	CITATIONS
77	Immunohistochemistry in bone marrow pathology: a useful adjunct for morphologic diagnosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 447, 920-937.	1.4	50
78	Follicular lymphoma: Management options in the era of targeted therapy. <i>Current Treatment Options in Oncology</i> , 2005, 6, 297-308.	1.3	5
79	Primary Colon Lymphoma in Korea: A KASID (Korean Association for the Study of Intestinal Diseases) Study. <i>Digestive Diseases and Sciences</i> , 2005, 50, 2243-2247.	1.1	61
80	A Case of Multiple Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma of the Colon Identified as Simple Mucosal Discoloration. <i>Journal of Korean Medical Science</i> , 2005, 20, 325.	1.1	21
81	Leukemia and Lymphoma of Natural Killer Cells. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2005, 45, 51-70.	0.3	23
82	A 61-Year-Old Man with Dyspepsia and Weight Loss. <i>PLoS Medicine</i> , 2005, 2, e154.	3.9	1
83	BEST PRACTICE No 185 Cytological and molecular diagnosis of lymphoma. <i>Journal of Clinical Pathology</i> , 2005, 58, 561-567.	1.0	32
84	WHO Non-Hodgkin's Lymphoma Classification by Criterion-Based Report Review followed by Targeted Pathology Review: An Effective Strategy for Epidemiology Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 2213-2219.	1.1	27
85	Follicular Colonization of Nodal Marginal-Zone B-Cell Lymphoma Resembling Follicular Lymphoma: Report of 6 Cases. <i>International Journal of Surgical Pathology</i> , 2005, 13, 73-78.	0.4	10
86	Natural Killer T-Cell Lymphoma of the Tongue. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2005, 114, 55-57.	0.6	8
87	Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. <i>Blood</i> , 2005, 106, 3183-3190.	0.6	348
88	Accumulation of miR-155 and BIC RNA in human B cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 3627-3632.	3.3	1,295
89	Canine Indolent Nodular Lymphoma. <i>Veterinary Pathology</i> , 2006, 43, 241-256.	0.8	185
90	"In situ-like" mantle cell lymphoma: a report of two cases. <i>Journal of Clinical Pathology</i> , 2006, 59, 995-996.	1.0	54
91	Prognostic Evaluation of Nodal Diffuse Large B Cell Lymphoma by Immunohistochemical Profiles with Emphasis on CD138 Expression as a Poor Prognostic Factor. <i>Journal of Korean Medical Science</i> , 2006, 21, 397.	1.1	30
92	Primary Systemic Anaplastic Large Cell Lymphoma in a Single Korean Institution: Clinical Characteristics and Treatment Outcome. <i>Journal of Korean Medical Science</i> , 2006, 21, 633.	1.1	6
93	Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. <i>Blood</i> , 2006, 108, 1668-1676.	0.6	243
94	Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and does not correlate with p65 NF- κ B activation. <i>Modern Pathology</i> , 2006, 19, 891-898.	2.9	17

#	ARTICLE	IF	CITATIONS
95	Clinicopathologic implications of tissue inhibitor of metalloproteinase-1-positive diffuse large B-cell lymphoma. <i>Modern Pathology</i> , 2006, 19, 963-973.	2.9	9
96	High throughput tissue microarray analysis of FHIT expression in diffuse large cell B-cell lymphoma from Saudi Arabia. <i>Modern Pathology</i> , 2006, 19, 1124-1129.	2.9	5
97	Successful Treatment of Refractory Peripheral T-Cell Lymphoma with a Combination of Fludarabine and Cyclophosphamide. <i>International Journal of Hematology</i> , 2006, 83, 450-453.	0.7	5
98	Promoter Hypermethylation of the DNA-Repair Gene O ⁶ -Methylguanine-DNA Methyltransferase and p53 Mutation in Diffuse Large B-Cell Lymphoma. <i>International Journal of Hematology</i> , 2006, 84, 248-255.	0.7	21
99	Predictive Value of Prognostic Indices in Patients with Follicular Lymphomas. <i>Medical Oncology</i> , 2006, 23, 533-542.	1.2	3
100	Marginal zone lymphoma of both spleen and kidney displaying transformation into large B-cell lymphoma. <i>International Urology and Nephrology</i> , 2006, 38, 431-437.	0.6	2
101	Extranodal marginal zone B-cell lymphoma mimicking meningioma in lateral ventricle : a case report and possible pathogenesis. <i>Journal of Neuro-Oncology</i> , 2006, 80, 63-67.	1.4	26
102	Helicobacter pylori-negative / API2-MALT1 translocation-negative low-grade MALT lymphoma. <i>Gastric Cancer</i> , 2006, 9, 229-234.	2.7	3
103	Treatment of Burkitt lymphoma in children and adults: Lessons from Africa. <i>Current Hematologic Malignancy Reports</i> , 2006, 1, 230-240.	1.2	8
104	Lymphoblastic lymphoma in adults. <i>Current Hematologic Malignancy Reports</i> , 2006, 1, 241-247.	1.2	5
105	Gene arrays in lymphoma: Where will they fit in?. <i>Current Hematologic Malignancy Reports</i> , 2006, 1, 129-136.	1.2	6
106	Clinical and molecular prognostic factors in follicular lymphoma. <i>Current Oncology Reports</i> , 2006, 8, 358-367.	1.8	9
107	Findings of fluorine-18-FDG PET in extranodal origin lymphoma "In three cases of diffuse large B cell type lymphoma". <i>Annals of Nuclear Medicine</i> , 2006, 20, 689-693.	1.2	14
108	Striking male predominance of mantle cell lymphoma in Taiwan. <i>Journal of Clinical Pathology</i> , 2006, 59, 780-780.	1.0	4
109	Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. <i>Blood</i> , 2006, 107, 265-276.	0.6	1,392
110	Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists. <i>Journal of Clinical Pathology</i> , 2006, 60, 361-372.	1.0	144
111	Nodal aggressive B-cell lymphomas: a diagnostic approach. <i>Journal of Clinical Pathology</i> , 2007, 60, 1076-1085.	1.0	7
112	Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). <i>Blood</i> , 2007, 110, 695-708.	0.6	365

#	ARTICLE	IF	CITATIONS
113	Specific Secondary Genetic Alterations in Mantle Cell Lymphoma Provide Prognostic Information Independent of the Gene Expression-Based Proliferation Signature. <i>Journal of Clinical Oncology</i> , 2007, 25, 1216-1222.	0.8	166
114	Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. <i>Journal of Experimental Medicine</i> , 2007, 204, 633-643.	4.2	176
115	Evidence-Based Medicine for Rare Diseases: Implications for Data Interpretation and Clinical Trial Design. <i>Cancer Control</i> , 2007, 14, 160-166.	0.7	48
116	Hematologic manifestations of celiac disease. <i>Blood</i> , 2007, 109, 412-421.	0.6	307
117	The Diagnosis, Management, and Role of Hematopoietic Stem Cell Transplantation in Aggressive Peripheral T-Cell Neoplasms. <i>Cancer Control</i> , 2007, 14, 151-159.	0.7	7
118	Oral-Cutaneous CD4-Positive T-cell Lymphoma: A Study of Two Patients. <i>American Journal of Dermatopathology</i> , 2007, 29, 62-67.	0.3	14
119	Microarray Analysis of Gene Expression of Cancer to Guide the Use of Chemotherapeutics. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2007, 46, 222-229.	0.5	12
120	Fludarabine. <i>Drugs</i> , 2007, 67, 1633-1655.	4.9	37
121	MALT Lymphoma : Recent Advances in Aetiology and Molecular Genetics. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2007, 47, 31-42.	0.3	124
122	Primary Duodenal Mucosa-Associated Lymphoid Tissue (Malt) Lymphoma â€” a Rare Presentation of Gastric Outlet Obstruction. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2007, 21, 393-395.	1.8	9
123	Primary Hepatic Follicular Lymphoma: A Case Report and Discussion of Chemotherapy and Favorable Outcomes. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2007, 47, 73-77.	0.3	29
124	Synchronous Adenocarcinoma and Mantle Cell Lymphoma of the Stomach. <i>Yonsei Medical Journal</i> , 2007, 48, 1061.	0.9	4
125	Classification and Treatment of Rare and Aggressive Types of Peripheral T-Cell/Natural Killer-Cell Lymphomas of the Skin. <i>Cancer Control</i> , 2007, 14, 112-123.	0.7	18
126	Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. <i>Bone Marrow Transplantation</i> , 2007, 40, 239-243.	1.3	51
127	The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. <i>Bone Marrow Transplantation</i> , 2007, 40, 443-450.	1.3	96
128	MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course. <i>Leukemia</i> , 2007, 21, 1812-1818.	3.3	94
129	Absence of Chlamydial Infection in Japanese Patients with Ocular Adnexal Lymphoma of Mucosa-Associated Lymphoid Tissue. <i>International Journal of Hematology</i> , 2007, 85, 223-230.	0.7	37
130	Clinicopathologic Significance of Loss of CD19 Expression in Diffuse Large B-Cell Lymphoma. <i>International Journal of Hematology</i> , 2007, 85, 41-48.	0.7	9

#	ARTICLE	IF	CITATIONS
131	Detection of NOTCH1 Mutations in Adult T-Cell Leukemia/Lymphoma and Peripheral T-Cell Lymphoma. <i>International Journal of Hematology</i> , 2007, 85, 212-218.	0.7	15
132	Genetic polymorphisms of methylenetetrahydrofolate reductase and promoter methylation of MGMT and FHIT genes in diffuse large B cell lymphoma risk in Middle East. <i>Annals of Hematology</i> , 2007, 86, 887-895.	0.8	19
137	Follicular Lymphoma with Extensive Gastrointestinal Tract Involvement: Follow-up by Capsule Endoscopy. <i>Digestive Diseases and Sciences</i> , 2007, 52, 1031-1035.	1.1	8
138	Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. <i>Supportive Care in Cancer</i> , 2007, 15, 877-884.	1.0	33
139	Crystal-storing histiocytosis associated with MALT lymphoma of the ocular adnexa: a case report with review of literature. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 103-108.	1.4	30
140	Presentation of two cases of nasal type NK/T-cell lymphoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2007, 264, 39-43.	0.8	7
141	Usefulness of FDG PET for diagnosis and radiotherapy of the patient with malignant lymphoma involving bone marrow. <i>Radiation Medicine</i> , 2007, 25, 130-134.	0.8	1
142	Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. <i>Cancer Causes and Control</i> , 2008, 19, 841-858.	0.8	87
143	Genomic deletion and promoter methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle cell lymphoma. <i>Journal of Hematopathology</i> , 2008, 1, 85-95.	0.2	4
145	Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin's lymphoma?. <i>Annals of Nuclear Medicine</i> , 2008, 22, 23-30.	1.2	18
146	Primary mantle-cell non-Hodgkin's lymphoma of the tongue. <i>International Journal of Hematology</i> , 2008, 88, 206-208.	0.7	17
147	Unexpected finding of laparoscopic appendectomy: appendix MALT lymphoma in children. <i>Pediatric Surgery International</i> , 2008, 24, 471-473.	0.6	11
148	Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma. <i>Cancer</i> , 2008, 113, 508-514.	2.0	220
149	The role of viral and bacterial pathogens in gastrointestinal cancer. <i>Journal of Cellular Physiology</i> , 2008, 216, 378-388.	2.0	46
150	Hematopoietic SCT for peripheral T-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2008, 42, 773-781.	1.3	21
151	Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2008, 41, 715-720.	1.3	21
152	NOD/SCID mouse model of canine T-cell lymphoma with humoral hypercalcaemia of malignancy: cytokine gene expression profiling and in vivo bioluminescent imaging. <i>Veterinary and Comparative Oncology</i> , 2008, 6, 39-54.	0.8	15
153	Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. <i>British Journal of Haematology</i> , 2008, 143, 395-403.	1.2	97

#	ARTICLE	IF	CITATIONS
154	<i>MYC</i> translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. <i>Histopathology</i> , 2008, 53, 205-217.	1.6	114
155	Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. <i>Molecular Cancer</i> , 2008, 7, 40.	7.9	56
156	Diffuse Large B Cell Lymphoma: From Gene Expression Profiling to Prediction of Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 108-111.	2.0	14
157	Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 13520-13525.	3.3	868
158	A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). <i>Blood</i> , 2008, 112, 2248-2260.	0.6	199
159	Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. <i>Blood</i> , 2008, 112, 4384-4399.	0.6	336
160	Receptor-Directed Therapy of T-Cell Leukemias and Lymphomas. <i>Journal of Immunotoxicology</i> , 2008, 5, 235-248.	0.9	17
161	Cancer Waiting Times: What is the Value of a Lymphoma Waiting Time?. <i>Scottish Medical Journal</i> , 2008, 53, 5-7.	0.7	2
162	Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. <i>Annals of Oncology</i> , 2008, 19, 1935-1940.	0.6	73
163	Cervical Lymphadenopathy Resulting in a Diagnosis of Lymphoma. <i>Scottish Medical Journal</i> , 2008, 53, 13-16.	0.7	13
164	Comparison of Referring and Final Pathology for Patients With Non-Hodgkin's Lymphoma in the National Comprehensive Cancer Network. <i>Journal of Clinical Oncology</i> , 2008, 26, 5107-5112.	0.8	75
165	Small-molecule XIAP antagonist restores caspase-9-mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells. <i>Blood</i> , 2008, 111, 369-375.	0.6	35
166	Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. <i>Blood</i> , 2008, 111, 4463-4470.	0.6	292
167	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. <i>Blood</i> , 2008, 112, 3088-3098.	0.6	173
168	15. Treatment of Malignant Lymphoma. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2008, 97, 2315-2320.	0.0	0
169	Role of Peroxisome Proliferator-Activated Receptor Gamma and Its Ligands in the Treatment of Hematological Malignancies. <i>PPAR Research</i> , 2008, 2008, 1-18.	1.1	26
170	Risk of Non-Hodgkin Lymphoma Associated with Germline Variation in Genes that Regulate the Cell Cycle, Apoptosis, and Lymphocyte Development. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1259-1270.	1.1	59
171	Immunophenotypic Analysis of AIDS-Related Diffuse Large B-Cell Lymphoma and Clinical Implications in Patients From AIDS Malignancies Consortium Clinical Trials 010 and 034. <i>Journal of Clinical Oncology</i> , 2009, 27, 5039-5048.	0.8	89

#	ARTICLE	IF	CITATIONS
172	Improvements in Survival After Follicular Lymphoma by Race/Ethnicity and Socioeconomic Status: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 3044-3051.	0.8	31
173	EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies. <i>Clinical Cancer Research</i> , 2009, 15, 2514-2522.	3.2	57
174	Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant. <i>Immunotherapy</i> , 2009, 1, 809-824.	1.0	11
175	Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. <i>MAbs</i> , 2009, 1, 31-40.	2.6	33
177	Characterization of Follicular Lymphoma in the Small Intestine Using Double-Balloon Endoscopy. <i>Gastroenterology Research and Practice</i> , 2009, 2009, 1-5.	0.7	13
178	Genetic Polymorphisms in Nitric Oxide Synthase Genes Modify the Relationship between Vegetable and Fruit Intake and Risk of Non-Hodgkin Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1429-1438.	1.1	12
179	Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. <i>Annals of Oncology</i> , 2009, 20, 1080-1085.	0.6	132
180	Antibody-based therapy of leukaemia. <i>Expert Reviews in Molecular Medicine</i> , 2009, 11, e29.	1.6	34
181	Iterative Bayesian Model Averaging: a method for the application of survival analysis to high-dimensional microarray data. <i>BMC Bioinformatics</i> , 2009, 10, 72.	1.2	46
182	Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival. <i>American Journal of Hematology</i> , 2010, 85, 51-56.	2.0	22
183	Diffuse large B-cell lymphoma with a high number of epithelioid histiocytes (lymphoepithelioid B-cell) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Und Physiologie Und Fur Klinische Medizin, 2009, 455, 285-293.	1.4	9
184	Histopathological Image Analysis Using Model-Based Intermediate Representations and Color Texture: Follicular Lymphoma Grading. <i>Journal of Signal Processing Systems</i> , 2009, 55, 169-183.	1.4	163
185	Correlating Metabolic Activity with Cellular Proliferation in Follicular Lymphomas. <i>Molecular Imaging and Biology</i> , 2009, 11, 296-302.	1.3	29
186	Pralatrexate, a new hope for aggressive T-cell lymphomas?. <i>Clinical and Translational Oncology</i> , 2009, 11, 215-220.	1.2	9
187	The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis. <i>International Journal of Hematology</i> , 2009, 89, 326-331.	0.7	8
188	Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China. <i>International Journal of Hematology</i> , 2009, 90, 303-310.	0.7	15
189	Prognostic factors in low-grade non-Hodgkin lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 202-210.	1.2	13
190	Frontline therapy in mantle cell lymphoma: The role of high-dose therapy and integration of new agents. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 213-217.	1.2	5

#	ARTICLE	IF	CITATIONS
191	Mantle cell lymphoma: Are current therapies changing the course of disease?. <i>Current Oncology Reports</i> , 2009, 11, 371-377.	1.8	2
192	Prognostic impact of C-REL expression in diffuse large B-cell lymphoma. <i>Journal of Hematopathology</i> , 2009, 2, 20-26.	0.2	23
193	Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. <i>British Journal of Haematology</i> , 2009, 145, 173-179.	1.2	93
194	Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of today's knowledge. <i>Leukemia</i> , 2009, 23, 225-234.	3.3	192
195	Array-based DNA methylation profiling in follicular lymphoma. <i>Leukemia</i> , 2009, 23, 1858-1866.	3.3	65
196	t(11;18)(q21;q21) in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in stomach: a study of 48 cases. <i>Modern Pathology</i> , 2009, 22, 79-86.	2.9	12
197	Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2009, 44, 287-293.	1.3	6
198	Peripheral T-cell lymphoma presenting as an ischemic stroke in a 23-year-old woman: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2009, 3, 83.	0.4	4
199	Primary and Secondary T-cell Lymphomas of the Breast. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2009, 17, 301-306.	0.6	57
200	Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications. <i>Blood</i> , 2009, 113, 635-645.	0.6	52
201	HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 ^{low} expressing tumor cells that resist rituximab-mediated lysis. <i>Haematologica</i> , 2010, 95, 2063-2071.	1.7	28
202	The Mantle Cell Lymphoma International Prognostic Index: Does it work in routine practice?. <i>Oncology Letters</i> , 2010, 1, 187-188.	0.8	8
203	A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2010, 89, 1107-1113.	0.8	28
205	Nodal Follicular Lymphoma. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 191-196.	1.0	17
206	Gastrointestinal follicular lymphoma: review of the literature. <i>Journal of Gastroenterology</i> , 2010, 45, 370-388.	2.3	100
207	Epstein-Barr virus and Hodgkin's lymphoma in Cairo, Egypt. <i>Journal of Hematopathology</i> , 2010, 3, 11-18.	0.2	16
208	Concomitant renal cell carcinoma and lymphoid malignancies: a case series of five patients and review of the literature. <i>Medical Oncology</i> , 2010, 27, 55-58.	1.2	9
209	SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma. <i>Clinical and Translational Oncology</i> , 2010, 12, 760-764.	1.2	2

#	ARTICLE	IF	CITATIONS
210	F-18 FDG PET/CT evaluation of radiotherapy response in rare case of mucosa-associated lymphoid tissue lymphoma. <i>Annals of Nuclear Medicine</i> , 2010, 24, 115-119.	1.2	2
211	Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients. <i>International Journal of Hematology</i> , 2010, 91, 456-463.	0.7	22
212	Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. <i>International Journal of Hematology</i> , 2010, 92, 732-743.	0.7	37
213	Alcohol consumption and non-Hodgkin lymphoma survival. <i>Journal of Cancer Survivorship</i> , 2010, 4, 101-109.	1.5	19
214	Rare Pediatric Non-Hodgkin Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2010, 5, 163-168.	1.2	16
215	Prognostic Markers in Peripheral T-Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2010, 5, 222-228.	1.2	30
216	Should Eligible Patients with T-Cell Lymphoma Receive High-Dose Therapy and Autologous Stem Cell Transplant in the Upfront Setting?. <i>Current Oncology Reports</i> , 2010, 12, 374-382.	1.8	8
217	Risk of non-Hodgkin lymphoma and nitrate and nitrite from the diet in Connecticut women. <i>Cancer Causes and Control</i> , 2010, 21, 889-896.	0.8	18
218	Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia. <i>BMC Cancer</i> , 2010, 10, 231.	1.1	14
219	Clinical outcome of patients with follicular lymphoma and bulky disease after Rituximab+CHOP immunochemotherapy with and without consolidating radiotherapy. <i>European Journal of Haematology</i> , 2010, 85, 11-19.	1.1	4
220	Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. <i>Leukemia Research</i> , 2010, 34, 379-386.	0.4	26
221	Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer cell lymphomas. <i>British Journal of Haematology</i> , 2010, 150, 170-178.	1.2	44
222	A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , 2010, 102, 19-22.	2.9	14
223	Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. <i>Laboratory Investigation</i> , 2010, 90, 1346-1356.	1.7	33
224	Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. <i>Bone Marrow Transplantation</i> , 2010, 45, 311-316.	1.3	59
225	Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness. <i>ClinicoEconomics and Outcomes Research</i> , 2010, 2, 37.	0.7	3
226	Blood Disorders in the Elderly. , 2010, , 775-790.		0
227	Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type. <i>Advances in Hematology</i> , 2010, 2010, 1-5.	0.6	65

#	ARTICLE	IF	CITATIONS
228	Impact of Autologous and Allogeneic Stem Cell Transplantation in Peripheral T-Cell Lymphomas. <i>Advances in Hematology</i> , 2010, 2010, 1-12.	0.6	34
229	Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma. <i>OncoTargets and Therapy</i> , 2010, 3, 167.	1.0	6
230	Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management. <i>Haematologica</i> , 2010, 95, 1130-1135.	1.7	10
231	Constitutive Activity of Nuclear Transcription Factor β is Observed in Follicular Lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2010, 50, 45-50.	0.3	5
232	The Significance of Bone Marrow Involvement in Aggressive Lymphomas: A Retrospective Comparison of Clinical Outcomes between Peripheral T Cell Lymphoma and Diffuse Large B Cell Lymphoma in China. <i>Acta Haematologica</i> , 2010, 124, 239-244.	0.7	7
233	Vegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut women. <i>Leukemia and Lymphoma</i> , 2010, 51, 1047-1054.	0.6	32
234	Cytotoxic T Cells in <i>H. pylori</i> -Related Gastric Autoimmunity and Gastric Lymphoma. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-10.	3.0	41
235	The role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma. <i>Journal of Leukocyte Biology</i> , 2010, 87, 627-632.	1.5	28
236	I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma. <i>Molecular Cancer</i> , 2010, 9, 228.	7.9	14
237	Rituximab in Indolent Lymphomas. <i>Seminars in Hematology</i> , 2010, 47, 133-142.	1.8	31
238	F-18 fluorodeoxyglucose positron emission tomography and/or computed tomography findings of an unusual breast lymphoma case and concurrent cervical cancer: a case report. <i>Journal of Medical Case Reports</i> , 2010, 4, 282.	0.4	2
239	Non-Hodgkin's Lymphoma in the Elderly. <i>Drugs and Aging</i> , 2010, 27, 211-238.	1.3	7
240	Intratumoral plasmacytoid dendritic cells associate with increased survival in patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 1230-1238.	0.6	12
241	Economic impact of disease progression in follicular non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 2117-2123.	0.6	16
242	Classification of Canine Malignant Lymphomas According to the World Health Organization Criteria. <i>Veterinary Pathology</i> , 2011, 48, 198-211.	0.8	340
243	Clinical Features of Gastrointestinal Follicular Lymphoma: Comparison with Nodal Follicular Lymphoma and Gastrointestinal MALT Lymphoma. <i>Digestion</i> , 2011, 83, 191-197.	1.2	19
244	Mantle cell lymphoma of the maxillary sinus invading the orbit. <i>Optometry - Journal of the American Optometric Association</i> , 2011, 82, 22-31.	0.6	1
245	Current Status of Targeted Therapies for Mantle Cell Lymphoma. <i>Drugs</i> , 2011, 71, 2307-2326.	4.9	8

#	ARTICLE	IF	CITATIONS
246	The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. <i>Blood</i> , 2011, 117, 5019-5032.	0.6	1,681
247	Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. <i>Lancet Oncology</i> , The, 2011, 12, 361-368.	5.1	151
248	Molecular pathogenesis of diffuse large B-cell lymphoma. <i>Seminars in Diagnostic Pathology</i> , 2011, 28, 167-177.	1.0	72
249	Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type. <i>Tumor Biology</i> , 2011, 32, 913-920.	0.8	7
250	A Case of Monoclonal Gammopathy in Extranodal Marginal Zone B-cell Lymphoma of the Small Intestine. <i>Annals of Laboratory Medicine</i> , 2011, 31, 18-21.	1.2	7
251	Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma. <i>Therapeutics and Clinical Risk Management</i> , 2011, 7, 401.	0.9	1
252	Comparison of Long-Term Clinical Outcomes of CHOP Chemotherapy between Japanese Patients with Nodal Peripheral T-Cell Lymphomas and Those with Diffuse Large B-Cell Lymphoma in the Study Group of the Tohoku Hematology Forum. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2011, 51, 29-35.	0.3	9
253	Primary cutaneous B-cell lymphoblastic lymphoma in an elderly man. <i>The Korean Journal of Hematology</i> , 2011, 46, 283.	0.7	3
254	An update on the management of peripheral T-cell lymphoma and emerging treatment options. <i>Journal of Blood Medicine</i> , 2011, 2, 119.	0.7	5
255	Prognostic Value of Immunohistochemical Biomarkers at Different Cut-off Values in Patients with Diffuse Large B-cell Lymphoma Treated with CHOP Chemotherapy. <i>Journal of Korean Medical Science</i> , 2011, 26, 1556.	1.1	8
256	Identification and Characterization of Peripheral T-Cell Lymphoma-Associated SEREX Antigens. <i>PLoS ONE</i> , 2011, 6, e23916.	1.1	10
257	Resveratrol Suppresses Constitutive Activation of AKT via Generation of ROS and Induces Apoptosis in Diffuse Large B Cell Lymphoma Cell Lines. <i>PLoS ONE</i> , 2011, 6, e24703.	1.1	72
258	Current and Emerging Therapies in Peripheral T-cell Lymphoma: Focus on Pralatrexate. <i>Clinical Medicine Insights Therapeutics</i> , 2011, 3, CMT.S3778.	0.4	2
259	Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. <i>Blood</i> , 2011, 118, 2976-2984.	0.6	140
260	Significance of aldehyde dehydrogenase 1 expression in stromal cells of diffuse large B-cell lymphoma. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 591-594.	0.8	5
261	Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. <i>Haematologica</i> , 2011, 96, 1121-1127.	1.7	171
262	Primary Gastric Diffuse Large B-cell Lymphoma with Orbital Involvement: Diagnostic Usefulness of 18F-fluorodeoxyglucose Positron Emission Tomography. <i>Internal Medicine</i> , 2011, 50, 1953-1956.	0.3	4
263	Vc-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. <i>British Journal of Haematology</i> , 2011, 155, 190-197.	1.2	48

#	ARTICLE	IF	CITATIONS
264	Partitioning Histopathological Images: An Integrated Framework for Supervised Color-Texture Segmentation and Cell Splitting. <i>IEEE Transactions on Medical Imaging</i> , 2011, 30, 1661-1677.	5.4	174
265	Subtype distribution of lymphomas in Southwest China: Analysis of 6,382 cases using WHO classification in a single institution. <i>Diagnostic Pathology</i> , 2011, 6, 77.	0.9	186
266	Synchronous perforation of non-Hodgkin's lymphoma of the small intestine and colon: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 57.	0.4	3
267	Autoimmune phenomena in untreated and treated marginal zone lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2369-2379.	0.9	7
269	Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1401-1413.	1.1	5
271	Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: a Chinese study. <i>Medical Oncology</i> , 2011, 28, 241-248.	1.2	7
272	Hepatosplenic T-Cell Lymphoma. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2011, 27, 39-42.	0.3	8
273	The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2011, 27, 136-145.	0.3	1
274	Non-Hodgkin lymphoma in childhood and adolescence: frequency and distribution of immunomorphological types from a tertiary care center in South India. <i>World Journal of Pediatrics</i> , 2011, 7, 318-325.	0.8	16
275	Burkitt Lymphoma and Atypical Burkitt or Burkitt-like Lymphoma: Should These be Treated as Different Diseases?. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 58-66.	1.2	22
276	Primary Mediastinal DLBCL: Evolving Biologic Understanding and Therapeutic Strategies. <i>Current Oncology Reports</i> , 2011, 13, 407-415.	1.8	15
277	Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations. <i>Herpesviridae</i> , 2011, 2, 8.	2.7	40
278	CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma. <i>Modern Pathology</i> , 2011, 24, 993-1003.	2.9	29
279	Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. <i>Leukemia and Lymphoma</i> , 2011, 52, 1675-1680.	0.6	38
280	Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 2787-2794.	0.8	230
281	Revisiting the Marrow Metabolic Changes after Chemotherapy in Lymphoma: A Step towards Personalized Care. <i>International Journal of Molecular Imaging</i> , 2011, 2011, 1-6.	1.3	3
282	Extranodal MALT Lymphoma of the Right Triceps Muscle following Influenza Vaccine Injection: A Rare Case with an Interesting Presentation. <i>ISRN Hematology</i> , 2011, 2011, 1-3.	1.6	11
283	Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 1182-1189.	0.8	535

#	ARTICLE	IF	CITATIONS
284	Transferrin Receptor Expression in Canine Lymphoma. <i>Veterinary Pathology</i> , 2011, 48, 466-474.	0.8	4
285	Gene expression profiling in follicular lymphoma and its implication for clinical practice. <i>Leukemia and Lymphoma</i> , 2011, 52, 59-68.	0.6	13
286	Centralized Review Offers Promise for the Clinician, the Pathologist, and the Patient With Newly Diagnosed Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1398-1399.	0.8	4
287	European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. <i>Haematologica</i> , 2012, 97, 360-365.	1.7	87
288	Clinicopathological Features and Outcomes of T- and NK-Cell Lymphomas in European Russia. <i>Clinical Medicine Blood Disorders</i> , 2012, 5, CMBD.S7804.	0.2	0
289	Indolent B-Cell Lymphomas Associated with HCV Infection: Clinical and Virological Features and Role of Antiviral Therapy. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-10.	3.3	55
290	Automated Analysis of Multidimensional Flow Cytometry Data Improves Diagnostic Accuracy Between Mantle Cell Lymphoma and Small Lymphocytic Lymphoma. <i>American Journal of Clinical Pathology</i> , 2012, 137, 75-85.	0.4	36
291	Early stage follicular lymphoma, current management and controversies. <i>Current Opinion in Oncology</i> , 2012, 24, 475-479.	1.1	11
292	Infectious mononucleosis mimicking lymphoma: distinguishing morphological and immunophenotypic features. <i>Modern Pathology</i> , 2012, 25, 1149-1159.	2.9	72
293	The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies. <i>Laboratory Investigation</i> , 2012, 92, 1574-1582.	1.7	71
294	Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies. <i>Blood Cancer Journal</i> , 2012, 2, e65-e65.	2.8	22
295	Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model. <i>Blood Cancer Journal</i> , 2012, 2, e67-e67.	2.8	11
296	How to predict the outcome in mature T and NK cell lymphoma by currently used prognostic models?. <i>Blood Cancer Journal</i> , 2012, 2, e93-e93.	2.8	14
297	Tailored Therapy in an Unselected Population of 91 Elderly Patients with DLBCL Prospectively Evaluated Using a Simplified CGA. <i>Oncologist</i> , 2012, 17, 663-672.	1.9	52
298	Endoscopic ultrasound and endobronchial ultrasound-guided fine-needle aspiration of deep-seated lymphadenopathy: Analysis of 1338 cases. <i>CytoJournal</i> , 2012, 9, 14.	0.8	26
299	Novel Therapies for Aggressive B-Cell Lymphoma. <i>Advances in Hematology</i> , 2012, 2012, 1-22.	0.6	16
300	Lenalidomide in Diffuse Large B-Cell Lymphomas. <i>Advances in Hematology</i> , 2012, 2012, 1-5.	0.6	12
301	Exploring Risk Factors for Follicular Lymphoma. <i>Advances in Hematology</i> , 2012, 2012, 1-13.	0.6	29

#	ARTICLE	IF	CITATIONS
302	Lenalidomide in Diffuse Large B-Cell Lymphoma. <i>Advances in Hematology</i> , 2012, 2012, 1-8.	0.6	18
303	Radiological Findings of a 57-Year-Old Male with Follicular Lymphoma of the Mandible. <i>Proceedings of Singapore Healthcare</i> , 2012, 21, 88-90.	0.2	0
304	A general framework for the segmentation of follicular lymphoma virtual slides. <i>Computerized Medical Imaging and Graphics</i> , 2012, 36, 442-451.	3.5	30
305	Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. <i>Blood</i> , 2012, 120, 4635-4644.	0.6	83
306	Rituximab. <i>BioDrugs</i> , 2012, 26, 71-82.	2.2	15
307	Considerations in the initial management of follicular lymphoma. <i>Community Oncology</i> , 2012, 9, S53-S60.	0.2	6
308	An efficient computational framework for the analysis of whole slide images: Application to follicular lymphoma immunohistochemistry. <i>Journal of Computational Science</i> , 2012, 3, 269-279.	1.5	34
309	Dietary Nitrate and Nitrite Intake and Non-Hodgkin Lymphoma Survival. <i>Nutrition and Cancer</i> , 2012, 64, 488-492.	0.9	7
310	Prognostic factors of Chinese patients with T/NK-cell lymphoma: a single institution study of 170 patients. <i>Medical Oncology</i> , 2012, 29, 2176-2182.	1.2	23
311	Angioimmunoblastic T-cell lymphoma: the effect of initial treatment and microvascular density in 31 patients. <i>Medical Oncology</i> , 2012, 29, 2311-2316.	1.2	6
312	Expression of Spy1 protein in human Non-Hodgkin's Lymphomas is correlated with phosphorylation of p27Kip1 on Thr187 and cell proliferation. <i>Medical Oncology</i> , 2012, 29, 3504-3514.	1.2	27
313	Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study. <i>Annals of Hematology</i> , 2012, 91, 1747-1756.	0.8	14
314	Gastrointestinal Mantle Cell Lymphoma—A Tale of Two Endoscopies. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 20-24.	0.6	2
315	Mantle cell lymphoma of the larynx: Primary case report. <i>Journal of Medical Case Reports</i> , 2012, 6, 201.	0.4	5
316	Germinal Center B-Cell-Like versus Non-Germinal Center B-Cell-Like as Important Prognostic Factor for Localized Nodal DLBCL. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2012, 52, 91-99.	0.3	9
317	Tonsillar follicular lymphoma in a child. <i>BMJ Case Reports</i> , 2012, 2012, bcr2012006848-bcr2012006848.	0.2	2
318	Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients. <i>Scientific World Journal, The</i> , 2012, 2012, 1-7.	0.8	10
319	ALK+ anaplastic large cell lymphoma exhibits phosphatidylinositol 3-kinase/akt activity with retained but inactivated PTEN—A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2012, 59, 440-447.	0.8	6

#	ARTICLE	IF	CITATIONS
320	EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. <i>Leukemia</i> , 2012, 26, 1908-1975.	3.3	738
321	Increasing incidence of enteropathy-associated T-cell lymphoma in the United States, 1973-2008. <i>Cancer</i> , 2012, 118, 3786-3792.	2.0	51
322	Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma. Current Treatment Options in <i>Oncology</i> , 2012, 13, 82-101.	1.3	4
323	Uncommon Late Relapse of Angioimmunoblastic T-Cell Lymphoma after 16-Year Remission Period. <i>Pathology and Oncology Research</i> , 2012, 18, 737-741.	0.9	0
324	Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. <i>Journal of Cancer Survivorship</i> , 2012, 6, 102-114.	1.5	18
325	Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. <i>Investigational New Drugs</i> , 2012, 30, 368-375.	1.2	17
326	Diffuse swelling of the buccal mucosa and palate as first and only manifestation of an extranodal non-Hodgkin "double-hit" lymphoma: report of a case. <i>Oral and Maxillofacial Surgery</i> , 2012, 16, 69-74.	0.6	10
327	Treatment of Adolescents with Aggressive B-Cell Malignancies: The Pediatric Experience. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 226-235.	1.2	7
328	Prognostic value of Waldeyer's ring involvement of diffuse large B-cell lymphoma treated with R-CHOP. <i>International Journal of Hematology</i> , 2013, 97, 397-402.	0.7	10
329	Prognosis of mature T cell lymphoma is poorer than that of diffuse large B cell lymphoma in IPI low-risk group, but not in intermediate- and high-risk groups. <i>International Journal of Hematology</i> , 2013, 97, 98-102.	0.7	5
330	Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 123-126.	0.3	1
331	Simple but powerful prognostic scoring model for MALT lymphoma: a retrospective study. <i>Annals of Hematology</i> , 2013, 92, 421-423.	0.8	1
333	Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 507-516.	13.9	1,449
334	Canine Lymphomas. <i>Veterinary Pathology</i> , 2013, 50, 738-748.	0.8	202
335	Anthracycline-containing regimens for treatment of follicular lymphoma in adults. <i>The Cochrane Library</i> , 2013, , CD008909.	1.5	4
336	Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement. <i>Journal of Hematology and Oncology</i> , 2013, 6, 76.	6.9	18
337	MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas. <i>Infectious Agents and Cancer</i> , 2013, 8, 37.	1.2	12
338	Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2013, 6, 69.	6.9	18

#	ARTICLE	IF	CITATIONS
339	Racial differences in chronic lymphocytic leukemia. <i>Cancer</i> , 2013, 119, 3593-3595.	2.0	11
340	Expression of DBC1 and Androgen Receptor Predict Poor Prognosis in Diffuse Large B Cell Lymphoma. <i>Translational Oncology</i> , 2013, 6, 370-381.	1.7	27
341	Inhibition of miR-21 Induces Biological and Behavioral Alterations in Diffuse Large B-Cell Lymphoma. <i>Acta Haematologica</i> , 2013, 130, 87-94.	0.7	35
342	Current and Emerging Therapies in Mantle Cell Lymphoma. <i>Current Treatment Options in Oncology</i> , 2013, 14, 198-211.	1.3	14
343	Nodal and leukemic small B-cell neoplasms. <i>Modern Pathology</i> , 2013, 26, S15-S28.	2.9	9
344	Examining racial differences in diffuse large B-cell lymphoma presentation and survival. <i>Leukemia and Lymphoma</i> , 2013, 54, 268-276.	0.6	50
345	The Predictive Value of Interim and Final [18F] Fluorodeoxyglucose Positron Emission Tomography after Rituximab-Chemotherapy in the Treatment of Non-Hodgkin's Lymphoma: A Meta-Analysis. <i>BioMed Research International</i> , 2013, 2013, 1-8.	0.9	16
346	Low GILT Expression is Associated with Poor Patient Survival in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Immunology</i> , 2013, 4, 425.	2.2	28
347	Biostable ssDNA Aptamers Specific for Hodgkin Lymphoma. <i>Sensors</i> , 2013, 13, 14543-14557.	2.1	6
348	Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity. <i>PLoS Genetics</i> , 2013, 9, e1003137.	1.5	102
349	Transformation of Follicular Lymphoma to Epstein-Barr Virus-Related Hodgkin-Like Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, e53-e56.	0.8	16
350	Novel agents in indolent lymphomas. <i>Therapeutic Advances in Hematology</i> , 2013, 4, 133-148.	1.1	13
351	Inter-reader variability in follicular lymphoma grading: Conventional and digital reading. <i>Journal of Pathology Informatics</i> , 2013, 4, 30.	0.8	20
352	Follicular Lymphoma <i>In Situ</i> Presenting as Dermatopathic Lymphadenopathy. <i>Case Reports in Pathology</i> , 2013, 2013, 1-4.	0.2	1
353	Stage IAE Follicular Lymphoma of the Breast: Case Report and Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2013, 2013, 1-3.	0.2	2
354	Cross Talk between Follicular Th Cells and Tumor Cells in Human Follicular Lymphoma Promotes Immune Evasion in the Tumor Microenvironment. <i>Journal of Immunology</i> , 2013, 190, 6681-6693.	0.4	77
355	MIB-1 labeling index as a prognostic factor for patients with follicular lymphoma treated with rituximab plus CHOP therapy. <i>Cancer Science</i> , 2013, 104, 1670-1674.	1.7	13
356	Clinicopathological prognostic indicators in 107 patients with diffuse large B-cell lymphoma transformed from follicular lymphoma. <i>Cancer Science</i> , 2013, 104, 952-957.	1.7	8

#	ARTICLE	IF	CITATIONS
357	Body Mass Index, Weight Change, and Survival in Non-Hodgkin Lymphoma Patients in Connecticut Women. <i>Nutrition and Cancer</i> , 2013, 65, 43-50.	0.9	18
358	Smurf2 suppresses B-cell proliferation and lymphomagenesis by mediating ubiquitination and degradation of YY1. <i>Nature Communications</i> , 2013, 4, 2598.	5.8	55
359	Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3688-3695.	0.8	320
360	Prognostic impact of concordant and discordant cytomorphology of bone marrow involvement in patients with diffuse, large, B-cell lymphoma treated with R-CHOP. <i>Journal of Clinical Pathology</i> , 2013, 66, 420-425.	1.0	22
361	Regression of Follicular Lymphoma of the Duodenum Following Eradication of <i>Helicobacter pylori</i> Infection. <i>Internal Medicine</i> , 2013, 52, 2611-2614.	0.3	10
362	Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. <i>Blood</i> , 2013, 122, 981-987.	0.6	225
365	Management of mantle cell lymphoma in the elderly patient. <i>Clinical Interventions in Aging</i> , 2013, 8, 1229.	1.3	11
366	Waldenstrom's macroglobulinemia presenting with lytic bone lesions: a rare presentation. <i>Blood Research</i> , 2013, 48, 230.	0.5	5
367	Implant-associated anaplastic large cell lymphoma of the breast: Insight into a poorly understood disease. <i>Canadian Journal of Plastic Surgery</i> , 2013, 21, 95-98.	0.4	21
368	Improving but Inferior Survival in Patients with Chronic Lymphocytic Leukemia in Taiwan: A Population-Based Study, 1990-2004. <i>PLoS ONE</i> , 2013, 8, e62930.	1.1	17
369	Early Stage W.H.O. Grade I and II Follicular Lymphoma Treated with Radiation Therapy Alone. <i>PLoS ONE</i> , 2013, 8, e65156.	1.1	16
370	Molecular pathology of lymphoma. , 0, , 738-750.		0
371	Influence of NK cell count on the survival of patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Blood Research</i> , 2014, 49, 162.	0.5	15
372	Simultaneous Inhibition of CXCR4 and VLA-4 Exhibits Combinatorial Effect in Overcoming Stroma-Mediated Chemotherapy Resistance in Mantle Cell Lymphoma Cells. <i>Immune Network</i> , 2014, 14, 296.	1.6	12
373	Case series of precursor B-cell lymphoblastic lymphoma. <i>Blood Research</i> , 2014, 49, 270.	0.5	1
374	The prognostic value of mid- and post-treatment [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma. <i>Annals of Nuclear Medicine</i> , 2014, 28, 805-811.	1.2	22
375	Value of multidetector computed tomography in the diagnosis of mucosa-associated lymphoid tissue-lymphomas in the parotid gland: A case report and review of the literature. <i>Oncology Letters</i> , 2014, 7, 781-786.	0.8	5
376	MicroRNA and gene networks in human diffuse large B-cell lymphoma. <i>Oncology Letters</i> , 2014, 8, 2225-2232.	0.8	10

#	ARTICLE	IF	CITATIONS
377	Prognostic value of bone marrow involvement by clonal immunoglobulin gene rearrangements in follicular lymphoma. <i>Journal of Clinical Pathology</i> , 2014, 67, 1072-1077.	1.0	14
378	A rare case of non-invasive ductal carcinoma of the breast coexisting with follicular lymphoma: A case report with a review of the literature. <i>Oncology Letters</i> , 2014, 7, 1001-1006.	0.8	10
379	Impact of Karyotype Organization on Interlocus Recombination between T Cell Receptor Genes in Equidae. <i>Cytogenetic and Genome Research</i> , 2014, 144, 306-314.	0.6	1
380	The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. <i>Cancer</i> , 2014, 120, 1830-1837.	2.0	33
381	Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. <i>BMC Cancer</i> , 2014, 14, 153.	1.1	102
382	Clinical Significance of MYC Expression and/or "High-grade" Morphology in Non-Burkitt, Diffuse Aggressive B-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2014, 38, 494-501.	2.1	43
383	Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group. <i>International Journal of Hematology</i> , 2014, 100, 281-289.	0.7	8
384	Epigenetic Function of Activation-Induced Cytidine Deaminase and Its Link to Lymphomagenesis. <i>Frontiers in Immunology</i> , 2014, 5, 642.	2.2	25
385	Primary mediastinal large B-cell lymphoma: Clinical features, prognostic factors and survival with RCHOP in Arab patients in the PET scan era. <i>Lung India</i> , 2014, 31, 228.	0.3	4
386	A Rare Presentation of In Situ Mantle Cell Lymphoma and Follicular Lymphoma: A Case Report and Review of the Literature. <i>Case Reports in Hematology</i> , 2014, 2014, 1-7.	0.3	7
387	Coexisting Mantle Cell Lymphoma and Prostate Adenocarcinoma. <i>Case Reports in Medicine</i> , 2014, 2014, 1-4.	0.3	10
388	Disruption of chromosomal locus 1p36 differentially modulates TAp73 and "Np73 expression in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2924-2931.	0.6	3
389	FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 565-574.	3.3	135
390	Ibrutinib in B-cell Lymphomas. <i>Current Treatment Options in Oncology</i> , 2014, 15, 226-237.	1.3	14
391	Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era. <i>Blood</i> , 2014, 123, 3553-3562.	0.6	78
392	Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. <i>Cancer</i> , 2014, 120, 1993-1999.	2.0	36
393	Long-term efficacy of 90Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life. <i>Annals of Hematology</i> , 2014, 93, 1985-1992.	0.8	9
394	Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1311-1318.	5.1	239

#	ARTICLE	IF	CITATIONS
395	Clinical Aspects of Malt Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 262-272.	1.2	17
397	<i>Helicobacter pylori</i> -related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity. <i>Blood Cancer Journal</i> , 2014, 4, e220-e220.	2.8	43
398	Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. <i>International Journal of Cancer</i> , 2014, 135, 2834-2846.	2.3	31
399	The tumour microenvironment in B cell lymphomas. <i>Nature Reviews Cancer</i> , 2014, 14, 517-534.	12.8	417
400	Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock. <i>Frontiers of Medicine</i> , 2014, 8, 254-258.	1.5	0
401	Quercetin Potentiates the Antitumor Activity of Rituximab in Diffuse Large B-Cell Lymphoma by Inhibiting STAT3 Pathway. <i>Cell Biochemistry and Biophysics</i> , 2014, 70, 1357-1362.	0.9	13
402	MALT lymphoma of the small bowel with protein-losing enteropathy. <i>International Journal of Hematology</i> , 2014, 99, 198-201.	0.7	6
403	Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma. <i>International Journal of Hematology</i> , 2014, 99, 737-742.	0.7	31
404	Primary B-lymphoblastic lymphoma of gallbladder involving mandibular bone. <i>International Journal of Hematology</i> , 2014, 99, 790-793.	0.7	8
405	Ocular Adnexal Lymphomas: Report of 2 Cases of Mantle Cell Lymphomas and Short Review of Literature. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2014, 30, 163-168.	0.3	6
406	Prognostic Value of Metabolic Tumor Volume Estimated by ^{18}F -FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 187-195.	0.6	41
407	Medical History, Lifestyle, Family History, and Occupational Risk Factors for Mantle Cell Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 76-86.	0.9	31
408	Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications. <i>Veterinary Immunology and Immunopathology</i> , 2014, 159, 192-201.	0.5	113
410	Non-Hodgkin's Lymphomas, Version 4.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1282-1303.	2.3	144
411	Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. <i>Haematologica</i> , 2014, 99, 125-130.	1.7	77
412	Simultaneous Occurrence of Early Gastric Carcinoma and Mucosa-Associated Lymphoid Tissue Lymphoma of the Omentum. <i>Case Reports in Gastroenterology</i> , 2014, 8, 101-106.	0.3	5
413	Role of radiotherapy in the treatment of primary mediastinal large B-cell lymphoma. <i>Oncology Letters</i> , 2015, 10, 2925-2930.	0.8	6
415	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 326-362.	2.3	46

#	ARTICLE	IF	CITATIONS
416	Ulcerative Colitis Diagnosed in a Patient after Primary Rectal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Treated. <i>Proceedings of Singapore Healthcare</i> , 2015, 24, 123-129.	0.2	0
417	Small Bowel Obstruction Due to MALT Lymphoma. <i>Journal of Diagnostic Medical Sonography</i> , 2015, 31, 173-175.	0.1	0
418	Classification of follicular lymphoma: the effect of computer aid on pathologists grading. <i>BMC Medical Informatics and Decision Making</i> , 2015, 15, 115.	1.5	30
419	Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001 (EMERGE) pivotal trial. <i>British Journal of Haematology</i> , 2015, 170, 496-503.	1.2	34
420	Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and I κ B κ kinase downregulation. <i>Anti-Cancer Drugs</i> , 2015, 26, 974-983.	0.7	6
421	Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable?. <i>Haematologica</i> , 2015, 100, 853-855.	1.7	3
422	New developments in the treatment of peripheral T-cell lymphoma – role of Belinostat. <i>Cancer Management and Research</i> , 2015, 7, 145.	0.9	10
423	Current trends in the treatment of primary mediastinal large B-cell lymphoma " an overview. <i>Wspolczesna Onkologia</i> , 2015, 6, 428-435.	0.7	4
424	Molecular Pathogenesis of MALT Lymphoma. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-10.	0.7	50
425	Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years. <i>PLoS ONE</i> , 2015, 10, e0131158.	1.1	22
426	Nodal Marginal Zone Large B-Cell Lymphoma with Burkitt Translocation and Complex Chromosomal Changes Associated with Overexpression of BCL2, MYC, and BCL6. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2015, 55, 175-180.	0.3	1
427	Persistent complete remission of acute leukemic-phase CCR4-positive gamma"delta peripheral T-cell lymphoma by autologous stem cell transplantation with mogamulizumab. <i>International Journal of Hematology</i> , 2015, 102, 498-505.	0.7	5
428	Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients. <i>Oncolmmunology</i> , 2015, 4, e990773.	2.1	27
429	High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. <i>Blood</i> , 2015, 126, 604-611.	0.6	130
430	Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2492-2499.	0.8	394
431	Discordant mycosis fungoides and cutaneous B-cell lymphoma: A case report and review of the literature. <i>JAAD Case Reports</i> , 2015, 1, 219-221.	0.4	2
432	Topotecan combined with Ifosfamide, Etoposide, and L-asparaginase (TIEL) regimen improves outcomes in aggressive T-cell lymphoma. <i>Medical Oncology</i> , 2015, 32, 402.	1.2	3
433	Clustering of CARMA1 through SH3"GUK domain interactions is required for its activation of NF- κ B signalling. <i>Nature Communications</i> , 2015, 6, 5555.	5.8	21

#	ARTICLE	IF	CITATIONS
434	CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. <i>Modern Pathology</i> , 2015, 28, 787-798.	2.9	27
435	Reticuloendothelial malignancy of head and neck: A comprehensive review. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2015, 7, 147.	0.2	1
436	The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma. <i>Leukemia</i> , 2015, 29, 958-967.	3.3	31
437	Comparing the Cost-Effectiveness of Rituximab Maintenance and Radioimmunotherapy Consolidation versus Observation Following First-Line Therapy in Patients with Follicular Lymphoma. <i>Value in Health</i> , 2015, 18, 189-197.	0.1	30
438	TET1 is a tumor suppressor of hematopoietic malignancy. <i>Nature Immunology</i> , 2015, 16, 653-662.	7.0	173
439	Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. <i>Annals of Hematology</i> , 2015, 94, 803-812.	0.8	74
440	Serum profiling by mass spectrometry combined with bioinformatics for the biomarkers discovery in diffuse large B-cell lymphoma. <i>Tumor Biology</i> , 2015, 36, 2193-2199.	0.8	11
441	A rare case of anasarca caused by infiltration of the pituitary gland by diffuse large B-cell lymphoma. <i>BMC Endocrine Disorders</i> , 2015, 15, 10.	0.9	3
442	Inhibition of human diffuse large B-cell lymphoma growth by JC polyomavirus-like particles delivering a suicide gene. <i>Journal of Translational Medicine</i> , 2015, 13, 29.	1.8	11
443	Current Therapeutic Strategies and New Treatment Paradigms for Follicular Lymphoma. <i>Cancer Treatment and Research</i> , 2015, 165, 197-226.	0.2	9
444	Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation. <i>Current Treatment Options in Oncology</i> , 2015, 16, 29.	1.3	2
445	Novel Targeted Therapies in Diffuse Large B-Cell Lymphoma. <i>Seminars in Hematology</i> , 2015, 52, 126-137.	1.8	24
446	Radical surgery may be not an optimal treatment approach for pulmonary MALT lymphoma. <i>Tumor Biology</i> , 2015, 36, 6409-6416.	0.8	15
447	Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study. <i>Annals of Oncology</i> , 2015, 26, 2311-2317.	0.6	22
448	<sc>ALK</sc>-positive (2p23 rearranged) anaplastic large cell lymphoma with localization to the skin in a pediatric patient. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 182-187.	0.7	30
449	Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma. <i>Bone Marrow Transplantation</i> , 2015, 50, 1299-1305.	1.3	7
450	Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2015, 94, 617-625.	0.8	13
451	Allogeneic Stem-Cell Transplantation for Peripheral T-Cell Lymphoma: A Systemic Review and Meta-Analysis. <i>Acta Haematologica</i> , 2015, 133, 136-144.	0.7	14

#	ARTICLE	IF	CITATIONS
452	Precursor B cell lymphoblastic lymphoma presenting as periorbital swelling. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016215679.	0.2	3
453	Early, Isolated Duodenal Mucosa-Associated Lymphoid Tissue Lymphoma Presenting without Symptoms or Grossly Apparent Endoscopic Lesions and Diagnosed by Random Duodenal Biopsies. <i>Case Reports in Gastroenterology</i> , 2016, 10, 323-331.	0.3	3
454	Clinical Outcomes after Allogeneic Stem Cell Transplantation for Adult Lymphoblastic Lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2016, 56, 28-33.	0.3	5
455	The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type. <i>Oncotarget</i> , 2016, 7, 58396-58404.	0.8	20
456	Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients. <i>Journal of Korean Medical Science</i> , 2016, 31, 1160.	1.1	8
457	The Comparative Diagnostic Features of Canine and Human Lymphoma. <i>Veterinary Sciences</i> , 2016, 3, 11.	0.6	60
458	Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China. <i>Intractable and Rare Diseases Research</i> , 2016, 5, 185-191.	0.3	134
459	Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review. <i>PLoS ONE</i> , 2016, 11, e0161811.	1.1	8
460	CT, MRI, and 18F-FDG PET/CT Findings in Untreated Pulmonary and Hepatic B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Over a Five-Year Period. <i>Medicine (United States)</i> , 2016, 95, e3197.	0.4	8
461	ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2016, 12, 1553-1563.	1.1	85
462	Clinical and histopathological evaluation of 16 dogs with T-zone lymphoma. <i>Journal of Veterinary Medical Science</i> , 2016, 78, 1237-1244.	0.3	34
463	Multifocal Gastric Ulcers Caused by Diffuse Large B Cell Lymphoma in a Patient With Significant Weight Loss. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2016, 4, 232470961668372.	0.3	0
464	MALT lymphoma of the left biceps muscle: a rare case with an interesting presentation. <i>SpringerPlus</i> , 2016, 5, 1194.	1.2	1
465	A Case Series of diffuse large B-cell lymphoma and burkitt lymphoma presenting with peritoneal lymphomatosis. <i>International Journal of Surgery Case Reports</i> , 2016, 28, 262-265.	0.2	11
466	T-cell Lymphoma Epidemiology: the Known and Unknown. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 492-503.	1.2	41
467	Prognostic factors in follicular lymphoma: new tools to personalize risk. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 269-276.	0.9	6
468	Surgical Management of Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Associated With Light-Chain Deposition Disease. <i>Annals of Thoracic Surgery</i> , 2016, 101, e207-e210.	0.7	1
469	Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1440-1448.	2.0	44

#	ARTICLE	IF	CITATIONS
470	FDG-PET imaging in hematological malignancies. <i>Blood Reviews</i> , 2016, 30, 317-331.	2.8	43
471	Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04). <i>International Journal of Hematology</i> , 2016, 103, 676-685.	0.7	6
472	Idelalisib for treatment of B-cell malignancies. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 547-555.	0.5	16
473	Elevated RNA expression of long non-coding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B cell lymphoma. <i>Molecular Medicine Reports</i> , 2016, 13, 5125-5131.	1.1	61
474	Radiotherapy for Non-Hodgkin's lymphoma: still standard practice and not an outdated treatment option. <i>Radiation Oncology</i> , 2016, 11, 110.	1.2	28
475	Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. <i>Haematologica</i> , 2016, 101, 1244-1250.	1.7	123
476	Modulation of p73 isoforms expression induces anti-proliferative and pro-apoptotic activity in mantle cell lymphoma independent of p53 status. <i>Leukemia and Lymphoma</i> , 2016, 57, 2874-2889.	0.6	2
477	⁹⁰ Yttrium-rituximab consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years. <i>Cancer Medicine</i> , 2016, 5, 1093-1097.	1.3	16
478	Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 567-576.	2.9	83
479	Detection of the value of consecutive serum total light chain (sTLC) in patients diagnosed with diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2016, 95, 1999-2007.	0.8	1
480	Gastrointestinal follicular lymphoma: using primary site as a predictor of survival. <i>Cancer Medicine</i> , 2016, 5, 2669-2677.	1.3	18
481	Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions. <i>Oncology Letters</i> , 2016, 12, 2782-2788.	0.8	7
482	Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 514-527.	1.2	149
483	Collision tumor consisting of primary follicular lymphoma and adenocarcinoma in the cecum: A case report and literature review. <i>Oncology Letters</i> , 2016, 11, 2801-2805.	0.8	17
484	CD10 down expression in follicular lymphoma correlates with gastrointestinal lesion involving the stomach and large intestine. <i>Cancer Science</i> , 2016, 107, 1687-1695.	1.7	15
485	An unusual presentation of gastric mucosa-associated lymphoid tissue (MALT)-type lymphoma. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2016, 6, 31707.	0.4	3
486	Subtype distribution of lymphomas in South of Iran, analysis of 1085 cases based on World Health Organization classification. <i>Annals of Hematology</i> , 2016, 95, 613-618.	0.8	11
487	Nodal Follicular Lymphomas: A Clinicopathological Study from a Tertiary Care Centre in South India. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2016, 32, 182-185.	0.3	0

#	ARTICLE	IF	CITATIONS
488	Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 175-181.	0.2	27
489	Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas. <i>Bone Marrow Transplantation</i> , 2016, 51, 654-662.	1.3	9
490	Mantle cell lymphoma with multiple lymphomatous polyposis and intussusception: A case report. <i>Oncology Letters</i> , 2016, 11, 654-656.	0.8	3
491	Activation of the Constitutive Androstane Receptor Increases the Therapeutic Index of CHOP in Lymphoma Treatment. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 392-401.	1.9	17
492	The Impact of DNA Methylation in Hematopoietic Malignancies. <i>Trends in Cancer</i> , 2016, 2, 70-83.	3.8	68
493	Recurrent activating mutations of CD28 in peripheral T-cell lymphomas. <i>Leukemia</i> , 2016, 30, 1062-1070.	3.3	107
494	Elucidation and Pharmacological Targeting of Novel Molecular Drivers of Follicular Lymphoma Progression. <i>Cancer Research</i> , 2016, 76, 664-674.	0.4	47
495	Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 380-385.	2.0	37
496	Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 235-239.	0.5	6
497	Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. <i>Expert Review of Hematology</i> , 2017, 10, 239-249.	1.0	104
498	Diagnosis and treatment of CD20 negative B cell lymphomas. <i>Biomarker Research</i> , 2017, 5, 5.	2.8	20
499	Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. <i>Blood</i> , 2017, 129, 2224-2232.	0.6	243
500	Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 99-115.	0.6	14
501	Unmet needs in the first-line treatment of follicular lymphoma. <i>Annals of Oncology</i> , 2017, 28, 2094-2106.	0.6	31
502	Prognostic Value of the Pretreatment Advanced Lung Cancer Inflammation Index (ALI) in Diffuse Large B Cell Lymphoma Patients Treated with R-CHOP Chemotherapy. <i>Acta Haematologica</i> , 2017, 137, 76-85.	0.7	38
503	A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. <i>Cancer</i> , 2017, 123, 1174-1183.	2.0	51
504	Lymphoproliferative Disorders of the Lung. <i>Respiration</i> , 2017, 94, 157-175.	1.2	48
505	Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?. <i>Bone Marrow Transplantation</i> , 2017, 52, 1487-1494.	1.3	17

#	ARTICLE	IF	CITATIONS
506	3D microvascular model recapitulates the diffuse large B-cell lymphoma tumor microenvironment in vitro. <i>Lab on A Chip</i> , 2017, 17, 407-414.	3.1	60
507	Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. <i>Annals of Hematology</i> , 2017, 96, 253-259.	0.8	22
508	Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies. <i>Leukemia and Lymphoma</i> , 2017, 58, 1702-1710.	0.6	10
509	T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw248.	3.0	28
510	Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Annals of Hematology</i> , 2017, 96, 405-410.	0.8	12
511	<sc>RB</sc> but not Râ€<sc>HCVAD</sc> is a feasible induction regimen prior to autoâ€<sc>HCT</sc> in frontline <sc>MCL</sc>: results of <sc>SWOG</sc> Study S1106. <i>British Journal of Haematology</i> , 2017, 176, 759-769.	1.2	40
512	Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793); Tj ETQq0 006gBT /Overlock 10	0.6	10
513	Epsteinâ€Barr virus (<sc>EBV</sc>) provides survival factors to <sc>EBV</sc> ⁺ diffuse large Bâ€cell lymphoma (<sc>DLBCL</sc>) lines and modulates cytokine induced specific chemotaxis in <sc>EBV</sc> ⁺ <sc>DLBCL</sc>. <i>Immunology</i> , 2017, 152, 562-573.	2.0	14
514	Breast implant-associated anaplastic large cell lymphoma: A review and assessment of cutaneous manifestations. <i>International Journal of Women's Dermatology</i> , 2017, 3, 140-144.	1.1	19
515	Perioperative Considerations for Chylothorax. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2017, 31, 2277-2281.	0.6	0
516	The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project. <i>Oncologist</i> , 2017, 22, 1415-1418.	1.9	7
517	Targeting the T cell receptor Î²-chain constant region for immunotherapy of T cell malignancies. <i>Nature Medicine</i> , 2017, 23, 1416-1423.	15.2	196
518	Lymphedema of the Lower Extremities due to Refractory Malignant Lymphoma Treated by Lymphaticovenous Anastomosis. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2017, 5, e1475.	0.3	4
519	Prognostic value of lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio in follicular lymphoma: a retrospective cohort study. <i>BMJ Open</i> , 2017, 7, e017904.	0.8	23
520	Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Haematologica</i> , 2017, 102, 2104-2112.	1.7	41
521	A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/Tâ€cell lymphoma, nasal type: a multicenter trial in Northwest China. <i>Hematological Oncology</i> , 2017, 35, 619-629.	0.8	19
522	Primary pituitary diffuse large B-cell lymphoma with somatotroph hyperplasia and acromegaly: case report. <i>Journal of Neurosurgery</i> , 2017, 126, 1725-1730.	0.9	19
523	WaldenstrÃm Macroglobulinaemia: Pathological Features and Diagnostic Assessment. , 2017, , 3-19.		0

#	ARTICLE	IF	CITATIONS
524	18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 589-597.	3.3	51
525	Different predictive values of interim 18F-FDG PET/CT in germinal center like and non-germinal center like diffuse large B-cell lymphoma. <i>Annals of Nuclear Medicine</i> , 2017, 31, 1-11.	1.2	9
526	Primary Mediastinal Large B-cell Lymphoma Presenting as a Bulky Anterior Mediastinal Tumor: A Case Report. <i>Journal of the Japanese Association of Rural Medicine</i> , 2017, 66, 86-90.	0.0	0
527	Interim 18F-FDG PET/CT improves the prognostic value of S-IPI, R-IPI and NCCN-IPI in patients with diffuse large B-cell lymphoma. <i>Oncology Letters</i> , 2017, 14, 6715-6723.	0.8	7
528	Hematopoietic cell transplants for mantle cell lymphoma. , 0, , 402-416.		0
529	High-Grade B-Cell Neoplasm with Surface Light Chain Restriction and Tdt Coexpression Evolved in aMYC-Rearranged Diffuse Large B-Cell Lymphoma: A Dilemma in Classification. <i>Case Reports in Hematology</i> , 2017, 2017, 1-9.	0.3	9
530	Pretreatment Liver Injury Predicts Poor Prognosis of DLBCL Patients. <i>Mediators of Inflammation</i> , 2017, 2017, 1-9.	1.4	3
531	T-Cell Non-Hodgkin Lymphomas: Spectrum of Disease and the Role of Imaging in the Management of Common Subtypes. <i>Korean Journal of Radiology</i> , 2017, 18, 71.	1.5	14
532	An essential EBV latent antigen 3C binds Bcl6 for targeted degradation and cell proliferation. <i>PLoS Pathogens</i> , 2017, 13, e1006500.	2.1	29
533	The role of B cell antigen receptors in mantle cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 164.	6.9	17
534	Lymphoblastic Lymphoma of the Palate. <i>Baylor University Medical Center Proceedings</i> , 2017, 30, 445-446.	0.2	0
535	Understanding rare adverse sequelae of breast implants: anaplastic large-cell lymphoma, late seromas, and double capsules. <i>Gland Surgery</i> , 2017, 6, 169-184.	0.5	83
536	Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. <i>Oncologist</i> , 2018, 23, 454-460.	1.9	22
537	Association of Soluble Interleukin-2 Receptor and C-Reactive Protein with the Efficacy of Bendamustine Salvage Treatment for Indolent Lymphomas and Mantle Cell Lymphoma. <i>Acta Haematologica</i> , 2018, 139, 12-18.	0.7	5
538	Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2. <i>Haematologica</i> , 2018, 103, 1182-1190.	1.7	34
539	Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy. <i>Current Oncology Reports</i> , 2018, 20, 33.	1.8	20
540	Impact of comorbidity on survival in peripheral T-cell lymphomas: A Swedish Lymphoma Registry study. <i>Hematological Oncology</i> , 2018, 36, 159-165.	0.8	10
541	FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. <i>Blood</i> , 2018, 131, 226-235.	0.6	31

#	ARTICLE	IF	CITATIONS
542	Small Bowel Obstruction Secondary to Ileal Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 207-210.	0.6	4
543	Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Medicine (United States)</i> , 2018, 97, e13046.	0.4	13
544	Secondary skin involvement in gastric diffuse large B-cell lymphoma treated with chidamide. <i>Medicine (United States)</i> , 2018, 97, e13093.	0.4	6
545	Review of Hematopathology Consult Cases: A Two-Year Experience in a Tertiary Referral Center in Lebanon. <i>BioMed Research International</i> , 2018, 2018, 1-9.	0.9	2
546	Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies. <i>Frontiers in Oncology</i> , 2018, 8, 556.	1.3	67
547	Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification. <i>Cancer Medicine</i> , 2018, 7, 5843-5858.	1.3	46
548	Novel Immunotherapies for T Cell Lymphoma and Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 494-506.	1.2	21
549	Leptin and its receptor in glucose metabolism of T-cell lymphoma. <i>Oncology Letters</i> , 2018, 16, 5838-5846.	0.8	7
550	KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma. <i>Diagnostic Pathology</i> , 2018, 13, 78.	0.9	15
551	De Novo CD5-Positive Primary Gastric Diffuse Large B-Cell Lymphoma Coexpressing MYC and BCL6: Towards a Proper Subset of Double-Hit, Triple-Hit and, Maybe, Quadruple-Hit B-Cell Lymphomas?. <i>Chonnam Medical Journal</i> , 2018, 54, 80.	0.5	2
552	MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis. <i>Cancer Cell</i> , 2018, 34, 453-465.e9.	7.7	68
553	Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas. <i>International Journal of Medical Sciences</i> , 2018, 15, 867-874.	1.1	14
554	Uptake of [18F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma. <i>Blood Advances</i> , 2018, 2, 649-655.	2.5	22
555	A prognostic model, including the EBV status of tumor cells, for primary gastric diffuse large B-cell lymphoma in the rituximab era. <i>Cancer Medicine</i> , 2018, 7, 3510-3520.	1.3	23
556	Primary Diffuse Large B Cell Lymphoma Mimicking Hyperplastic Reactive Lesion (Lymphoma of the Oral) Tj ETQq0 0,0,rgBT /Qyerlock 10	0.2	2
557	Breast Implant-Associated Anaplastic Large Cell Lymphoma: Case Report and Review of the Literature. <i>Case Reports in Hematology</i> , 2018, 2018, 1-6.	0.3	23
558	Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. <i>Cancer Management and Research</i> , 2018, Volume 10, 615-624.	0.9	24
559	Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3869-3882.	1.0	5

#	ARTICLE	IF	CITATIONS
560	Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2018, 11, 87.	6.9	12
561	Migratory polyarthrititis as a paraneoplastic syndrome in a patient with diffuse large B cell lymphoma: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 189.	0.4	3
562	Primary extra-nodal diffuse large B-cell lymphoma: A prognostic analysis of 141 patients. <i>Oncology Letters</i> , 2018, 16, 1602-1614.	0.8	22
563	Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial. <i>International Journal of Hematology</i> , 2018, 108, 499-509.	0.7	9
564	Diagnosis of Superficial Gastric Lesions Together with Six Gastric Lymphoma Cases via Probe-Based Confocal Laser Endomicroscopy: A Retrospective Observational Study. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-8.	0.7	6
565	Incidence and outcomes of lymphoid malignancies in adolescent and young adult patients in the United States. <i>British Journal of Haematology</i> , 2018, 183, 385-399.	1.2	24
566	Recent advances in understanding the biology of marginal zone lymphoma. <i>F1000Research</i> , 2018, 7, 406.	0.8	35
567	Clinical characteristics and prognostic significance of EBER positivity in diffuse large B-cell lymphoma: A meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0199398.	1.1	22
568	Pathogenesis of Enteropathy-Associated T Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 308-317.	1.2	49
569	HIV-triggered lymphoma. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 230-234.	0.3	1
570	Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. <i>Expert Review of Hematology</i> , 2019, 12, 833-843.	1.0	13
571	A multi-institutional and case-matched control study on treatment outcomes of consolidative radiotherapy after a full course of R-CHOP compared with R-CHOP alone in Stage II diffuse large B-cell lymphoma (KROG 17-02). <i>Journal of Radiation Research</i> , 2019, 60, 677-684.	0.8	3
572	Pixantrone beyond monotherapy: a review. <i>Annals of Hematology</i> , 2019, 98, 2025-2033.	0.8	10
573	Quantitative proteomic analysis of cerebrospinal fluid from patients with diffuse large B-cell lymphoma with central nervous system involvement: A novel approach to diagnosis. <i>Biomedical Reports</i> , 2019, 11, 70-78.	0.9	3
574	Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2815-2824.	0.8	173
575	Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites?. <i>Advances in Radiation Oncology</i> , 2019, 4, 507-512.	0.6	3
576	The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores. <i>International Journal of Hematology</i> , 2019, 110, 438-446.	0.7	7
577	Novel Aurora Kinase Inhibitor-Based Combination Therapies for PTCL. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
578	Phase II study of Râ€“CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. <i>Cancer Communications</i> , 2019, 39, 1-10.	3.7	12
579	Gastric MALT lymphoma refractory to <i>Helicobacter pylori</i> antibiotic therapy. <i>SAGE Open Medical Case Reports</i> , 2019, 7, 2050313X1986947.	0.2	0
580	Prognostic significance of DAPK promoter methylation in lymphoma: A meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0210943.	1.1	3
581	Case of Gastric Diffuse Large B-Cell Lymphoma. <i>Case Reports in Oncology</i> , 2019, 12, 39-46.	0.3	5
582	C-X-C Chemokine Receptor 4 in Diffuse Large B Cell Lymphoma: Achievements and Challenges. <i>Acta Haematologica</i> , 2019, 142, 64-70.	0.7	10
583	Treatment-associated outcomes of patients with primary ocular adnexal MALT lymphoma after accurate diagnosis. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1620-1628.	1.0	9
584	CD30⁺ large B cell lymphoma with anaplastic features and complete loss of B cell marker expression arising from follicular lymphoma. <i>Histopathology</i> , 2019, 75, 602-605.	1.6	3
585	Diffuse large B cell lymphoma primarily presenting as acute liver failure in a surviving patient. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2019, 9, 135-139.	0.4	6
586	Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large Bâ€“cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3. <i>Oncology Letters</i> , 2019, 17, 3719-3726.	0.8	12
587	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in nonâ€“follicular indolent Bâ€“cell lymphomas. <i>American Journal of Hematology</i> , 2019, 94, 658-666.	2.0	19
588	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1188-1199.	0.8	277
589	Turning Point in the Treatment of Mantle Cell Lymphoma. <i>Yonago Acta Medica</i> , 2019, 62, 001-007.	0.3	1
590	Lenalidomide plus rituximab (R²) in previously untreated marginal zone lymphoma: subgroup analysis and longâ€“term followâ€“up of an openâ€“label phase 2 trial. <i>British Journal of Haematology</i> , 2019, 185, 874-882.	1.2	37
591	Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma. <i>BMC Cancer</i> , 2019, 19, 322.	1.1	8
592	The Utility of Phosphohistone H3 (PHH3) in Follicular Lymphoma Grading: A Comparative Study With Ki-67 and H&E Mitotic Count. <i>American Journal of Clinical Pathology</i> , 2019, 151, 542-550.	0.4	10
593	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. <i>Blood Advances</i> , 2019, 3, 2013-2021.	2.5	40
594	Primary extranodal jejunal diffuse large B cell lymphoma as a diagnostic challenge for intractable emesis: a case report and review of literature. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2019, 9, 518-523.	0.4	3
595	Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions. <i>Journal of Hematology and Oncology</i> , 2019, 12, 141.	6.9	78

#	ARTICLE	IF	CITATIONS
596	18F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement. <i>Medicine (United States)</i> , 2019, 98, e14270.	0.4	1
597	Primary hepatic mucosa-associated lymphoid tissue lymphoma. <i>Medicine (United States)</i> , 2019, 98, e15034.	0.4	12
598	Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997â€“2016. <i>Medicine (United States)</i> , 2019, 98, e17641.	0.4	7
599	Mucosa-associated lymphoid tissue lymphoma with metachronous involvement of the palpebral conjunctiva and bronchus: A case report. <i>Respiratory Medicine Case Reports</i> , 2019, 26, 101-104.	0.2	0
600	Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995â€“2013: Findings from Texas and national SEER areas. <i>Cancer Epidemiology</i> , 2019, 58, 89-97.	0.8	5
601	Microfluidic assembly of hydrogel-based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release. <i>Journal of Controlled Release</i> , 2019, 295, 21-30.	4.8	52
602	Clinical presentation and characteristics of lymphoma in the head and neck region. <i>Head & Face Medicine</i> , 2019, 15, 1.	0.8	56
603	Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study. <i>Leukemia and Lymphoma</i> , 2019, 60, 1656-1667.	0.6	14
604	Prognostic analysis of interim 18F-FDG PET/CT in patients with diffuse large B cell lymphoma after one cycle versus two cycles of chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 478-488.	3.3	18
605	Validation of the Marginal Zone Lymphoma International Prognostic Index. <i>Annals of Hematology</i> , 2019, 98, 457-464.	0.8	11
606	Double or triple-expressor lymphomas: prognostic impact of immunohistochemistry in patients with diffuse large B-cell lymphoma. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 192-193.	0.1	7
607	Comparison of the Efficacy of Innovator Rituximab and its Biosimilars in Diffuse Large B Cell Lymphoma Patients: A Retrospective Analysis. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2020, 36, 71-77.	0.3	7
608	Utility of a Reverse Phase Protein Array to Evaluate Multiple Biomarkers in Diffuse Large B-Cell Lymphoma. <i>Proteomics - Clinical Applications</i> , 2020, 14, 1900091.	0.8	9
609	OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B-Cell lymphoma. <i>Cancer Medicine</i> , 2020, 9, 1790-1797.	1.3	10
610	Prognostic Value of Bone Marrow F-18 FDG Uptake in Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma. <i>Nuclear Medicine and Molecular Imaging</i> , 2020, 54, 28-34.	0.6	5
611	Extranodal marginal zone B-Cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients. <i>Cancer Medicine</i> , 2020, 9, 194-203.	1.3	13
613	Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma. <i>Journal of Biological Chemistry</i> , 2020, 295, 1165-1180.	1.6	21
614	High pretreatment plasma Epstein-Barr virus (EBV) DNA level is a poor prognostic marker in HIV-associated, EBV-negative diffuse large B-Cell lymphoma in Malawi. <i>Cancer Medicine</i> , 2020, 9, 552-561.	1.3	11

#	ARTICLE	IF	CITATIONS
615	Chemotherapy combined with radiotherapy for successful treatment of angioimmunoblastic T-cell lymphoma: a case report. <i>Journal of Medical Case Reports</i> , 2020, 14, 185.	0.4	1
616	A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib. <i>Annals of Hematology</i> , 2020, 99, 2715-2717.	0.8	2
617	Primary bladder mucosa-associated lymphoid tissue lymphoma. <i>Medicine (United States)</i> , 2020, 99, e20825.	0.4	6
618	Educational Case: Mantle Cell Lymphoma. <i>Academic Pathology</i> , 2020, 7, 237428952093228.	0.7	0
619	<p>The Expression of IgG and IgG4 in Orbital MALT Lymphoma: The Similarities and Differences of IgG4-Related Diseases</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5755-5761.	1.0	6
620	Genetic and epigenetic determinants of diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2020, 10, 123.	2.8	47
621	Dramatic radiotherapy response in a necrotic lymphoma mass: a case report. <i>Journal of Medical Case Reports</i> , 2020, 14, 118.	0.4	1
622	Unusual Case of Anaplastic Large Cell Lymphoma Presenting as a Breast Mass in a Patient with no History of Breast Implants. <i>Case Reports in Pathology</i> , 2020, 2020, 1-4.	0.2	2
623	Reply to M. Hertzberg et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 3723-3724.	0.8	0
624	Linking Immune Evasion and Metabolic Reprogramming in B-Cell-Derived Lymphomas. <i>Frontiers in Oncology</i> , 2020, 10, 594782.	1.3	13
625	Differential B-Cell Receptor Signaling Requirement for Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells. <i>Cancers</i> , 2020, 12, 1143.	1.7	7
626	Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma. <i>Hematological Oncology</i> , 2020, 38, 439-445.	0.8	4
627	STAT3 Mutation Is Associated with STAT3 Activation in CD30+ ALK ⁻ ALCL. <i>Cancers</i> , 2020, 12, 702.	1.7	17
628	RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group. <i>Annals of Hematology</i> , 2020, 99, 799-808.	0.8	21
629	Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents. <i>Annals of Pharmacotherapy</i> , 2020, 54, 879-898.	0.9	4
630	Insignificance of surveillance imaging in patients with diffuse large B-cell lymphoma who achieved first complete remission: a retrospective cohort study. <i>International Journal of Hematology</i> , 2020, 111, 567-573.	0.7	0
631	The clinical significance of the prognostic nutritional index in very elderly patients over 80 years of age with diffuse large B-cell lymphoma. <i>Annals of Hematology</i> , 2020, 99, 1153-1155.	0.8	6
632	<p>Clinical Analysis and Prognostic Significance of Hepatitis B Virus Infections with Diffuse Large B-Cell Lymphoma</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 2839-2851.	0.9	10

#	ARTICLE	IF	CITATIONS
633	BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas. <i>Cancers</i> , 2020, 12, 938.	1.7	55
634	Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma. <i>Annals of Hematology</i> , 2020, 99, 2837-2846.	0.8	9
635	Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study. <i>Blood</i> , 2020, 135, 1214-1218.	0.6	34
636	An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy. <i>Journal of Translational Medicine</i> , 2020, 18, 144.	1.8	10
637	Sequential Complications of Hypercalcemia, Necrotizing Granulomatous Vasculitis, and Aplastic Anemia Occurring in One Patient with Angioimmunoblastic T-cell Lymphoma. <i>American Journal of the Medical Sciences</i> , 2021, 361, 375-382.	0.4	2
638	Palatine Tonsils Primary Presentation of Blastoid Variant of Mantle Cell Lymphoma: Case Report. <i>Head and Neck Pathology</i> , 2021, 15, 588-592.	1.3	2
639	Identification of non-Hodgkin lymphoma patients at risk for treatment-related vertebral density loss and fractures. <i>Osteoporosis International</i> , 2021, 32, 281-291.	1.3	10
640	Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study â€” JCOG0108A. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2021, 61, 35-41.	0.3	0
641	Function of Deptor and its roles in hematological malignancies. <i>Aging</i> , 2021, 13, 1528-1564.	1.4	5
642	A Rare Entity in the Lumbar Epidural Region: T-Cell Lymphoblastic Lymphoma. <i>International Journal of Spine Surgery</i> , 2021, 14, S52-S56.	0.7	3
643	Bone Marrow Involvement by Aggressive B Cell Lymphoma Undetected by Aspirate Immunophenotyping. <i>Journal of Hematology (Brossard, Quebec)</i> , 2021, 10, 14-17.	0.4	1
644	Gastric mucosa-associated lymphoid tissue lymphoma with central nervous system involvement: a case report and 8-year follow-up. <i>Translational Cancer Research</i> , 2021, 10, 0-0.	0.4	0
645	Marginal zone lymphoma of the dura â€” two case reports with long-term follow-up. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021, 26, 138-142.	0.3	1
646	MALT Lymphoma of the Urinary Bladder Shows a Dramatic Female Predominance, Uneven Geographic Distribution, and Possible Infectious Etiology. <i>Research and Reports in Urology</i> , 2021, Volume 13, 49-62.	0.6	4
647	Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas. <i>Experimental Hematology and Oncology</i> , 2021, 10, 9.	2.0	24
648	Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma. <i>Experimental Hematology and Oncology</i> , 2021, 10, 15.	2.0	29
649	Emerging Role of Consolidative Radiotherapy After Complete Remission Following R-CHOP Immunochemotherapy in Stage IIIâ€”IV Diffuse Large B-Cell Lymphoma: A Single Institutional and Case-Matched Control Study. <i>Frontiers in Oncology</i> , 2021, 11, 578865.	1.3	1
650	A rare cause of right ventricle out flow tract obstruction: Anterior mediastinal teratoma. <i>Annals of Medicine and Surgery</i> , 2021, 62, 258-260.	0.5	0

#	ARTICLE	IF	CITATIONS
651	Low grade, indolent lymphomas of the head and neck: Comparative toxicity of standard versus very low dose radiation therapy. <i>Hematological Oncology</i> , 2021, 39, 304-312.	0.8	2
652	Primary Hepatic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in a Patient with Chronic Hepatitis B Virus Infection: Case Report and Summary of the Literature. <i>Medicina (Lithuania)</i> , 2021, 57, 280.	0.8	3
653	The role of whole-Body fluorine-18-fluorodeoxyglucose positron emission tomography in staging and surveillance of mucosa-associated lymphoid tissue. <i>Journal of Radiology Case Reports</i> , 2021, 15, 19-28.	0.2	0
654	Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial. <i>Blood Advances</i> , 2021, 5, 1695-1705.	2.5	18
655	Follicular Lymphoma in Young Adults: Study from a Regional Cancer Center in South India. <i>South Asian Journal of Cancer</i> , 2021, 10, 115-119.	0.2	0
656	DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set. <i>Scientific Data</i> , 2021, 8, 135.	2.4	11
657	Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma. <i>PLoS ONE</i> , 2021, 16, e0250839.	1.1	6
658	Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 10, 100126.	1.3	30
659	Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials. <i>Leukemia and Lymphoma</i> , 2021, 62, 2169-2176.	0.6	5
660	A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. <i>Cancer Science</i> , 2021, 112, 2845-2854.	1.7	24
661	Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group. <i>HemaSphere</i> , 2021, 5, e600.	1.2	3
662	Computational study on novel natural inhibitors targeting BCL2. <i>Medical Oncology</i> , 2021, 38, 94.	1.2	2
663	Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance. <i>BMC Cancer</i> , 2021, 21, 879.	1.1	3
664	Anti-TRBC1 Antibody-Based Flow Cytometric Detection of T-Cell Clonality: Standardization of Sample Preparation and Diagnostic Implementation. <i>Cancers</i> , 2021, 13, 4379.	1.7	17
665	Prognostic impact of nutritional and inflammation-based risk scores in follicular lymphoma in the era of anti-CD20 targeted treatment strategies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1789-1801.	1.2	5
666	One-Two Punch Therapy for the Treatment of T-Cell Malignancies Involving p53-Dependent Cellular Senescence. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-20.	1.9	8
667	An unusual presentation of non-IBD related colorectal primary extranodal diffuse large B cell lymphoma with a colo-colonic fistula. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2021, 11, 662-666.	0.4	2
668	Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 638757.	1.3	6

#	ARTICLE	IF	CITATIONS
669	The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma. <i>BMC Cancer</i> , 2021, 21, 82.	1.1	9
670	Maintenance therapy for untreated diffuse large B-cell lymphoma: a systematic review and network meta-analysis. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110188.	1.1	0
671	Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma. <i>PharmacoEconomics - Open</i> , 2021, 5, 175-186.	0.9	4
672	Impact of Genetics on Mature Lymphoid Leukemias and Lymphomas. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a035444.	2.9	1
673	Hodgkin's lymphoma: the pathologist's viewpoint. <i>Journal of Clinical Pathology</i> , 2002, 55, 162-176.	1.0	189
674	Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. <i>Journal of Clinical Investigation</i> , 2007, 117, 823-834.	3.9	272
675	Primary thyroid lymphoma: Can the diagnosis be made solely by fine-needle aspiration?. , 2002, 9, 298.		6
676	T Cell-Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation for Treatment of T-Lymphoblastic Lymphoma. <i>Annals of Transplantation</i> , 2018, 23, 427-433.	0.5	6
677	Recent advances in understanding and managing T-cell lymphoma. <i>F1000Research</i> , 2017, 6, 2123.	0.8	4
678	ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial. <i>F1000Research</i> , 2020, 9, 941.	0.8	3
679	Endoscopic features aiding the diagnosis of gastric mucosa-associated lymphoid tissue lymphoma. <i>Yeungnam University Journal of Medicine</i> , 2019, 36, 85-91.	0.7	14
680	Synchronous colonic mucosa-associated lymphoid tissue lymphoma found after surgery for adenocarcinoma: A case report and review of literature. <i>World Journal of Clinical Cases</i> , 2020, 8, 6456-6464.	0.3	2
681	Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data. <i>PLoS Biology</i> , 2004, 2, e108.	2.6	563
682	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. <i>PLoS Medicine</i> , 2016, 13, e1002197.	3.9	185
683	A Unified 35-Gene Signature for both Subtype Classification and Survival Prediction in Diffuse Large B-Cell Lymphomas. <i>PLoS ONE</i> , 2010, 5, e12726.	1.1	28
684	Metadherin Contributes to the Pathogenesis of Diffuse Large B-cell Lymphoma. <i>PLoS ONE</i> , 2012, 7, e39449.	1.1	29
685	Integrative Gene Expression Profiling Reveals G6PD-Mediated Resistance to RNA-Directed Nucleoside Analogues in B-Cell Neoplasms. <i>PLoS ONE</i> , 2012, 7, e41455.	1.1	11
686	Variation in Dicer Gene Is Associated with Increased Survival in T-Cell Lymphoma. <i>PLoS ONE</i> , 2012, 7, e51640.	1.1	22

#	ARTICLE	IF	CITATIONS
687	Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas. PLoS ONE, 2016, 11, e0146624.	1.1	8
688	HOXB4 Gene Expression Is Regulated by CDX2 in Intestinal Epithelial Cells. PLoS ONE, 2016, 11, e0164555.	1.1	1
689	Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry. PLoS ONE, 2017, 12, e0177204.	1.1	18
690	Primary Synovial Diffuse Large B-Cell Lymphoma Presenting as Loosening of Prosthetic Joint: A Case Report and Review of Literature. World Journal of Oncology, 2019, 10, 181-185.	0.6	7
691	Burkitt's lymphoma presenting with hypopituitarism: a case report and review of literature. Endocrinology, Diabetes and Metabolism Case Reports, 2014, 2014, 140029.	0.2	3
692	Cardiac Tamponade as Initial Presentation of Angioimmunoblastic T-Cell Lymphoma. Heart Surgery Forum, 2017, 20, 043.	0.2	1
693	The potential relevance of the endocannabinoid, 2-arachidonoylglycerol, in diffuse large B-cell lymphoma. Oncoscience, 2016, 3, 31-41.	0.9	17
694	NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma. Oncotarget, 2016, 7, 68513-68526.	0.8	48
695	Sites of extranodal involvement are prognostic in patients with stage 1 follicular lymphoma. Oncotarget, 2017, 8, 78410-78418.	0.8	9
696	Interim PET-CT may predict PFS and OS in T-ALL/LBL adult patients. Oncotarget, 2017, 8, 99104-99111.	0.8	5
697	Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma. Oncotarget, 2017, 8, 92312-92323.	0.8	11
698	Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas. Oncotarget, 2017, 8, 112516-112529.	0.8	32
699	Proliferative, pro-inflammatory, and angiogenesis regulator gene expression profile defines prognosis in different histopathological subtypes of nodal peripheral T-cell lymphoma. Oncotarget, 2019, 10, 5136-5151.	0.8	6
700	A Novel Probabilistic Nuclei Segmentation Algorithm for H&E Stained Histopathological Tissue Images. Journal of Polytechnic, 0, , .	0.4	2
701	Primary bone lymphoma: report of a case with multifocal skeletal involvement. Biomedical Imaging and Intervention Journal, 2007, 3, e52.	0.5	15
702	Construction and analysis of tree models for chromosomal classification of diffuse large B-cell lymphomas. World Journal of Gastroenterology, 2007, 13, 1737.	1.4	7
703	Treatment strategies for nodal and gastrointestinal follicular lymphoma: Current status and future development. World Journal of Gastroenterology, 2010, 16, 5543.	1.4	13
704	Mutational analysis of extranodal marginal zone lymphoma using next generation sequencing. Oncology Letters, 2020, 20, 1-1.	0.8	3

#	ARTICLE	IF	CITATIONS
705	Clinicopathologic Characteristics of T-cell Non-Hodgkin's Lymphoma: A Single Institution Experience. Korean Journal of Internal Medicine, 2009, 24, 128.	0.7	14
706	Non-gastric Marginal Zone B-cell Lymphoma in Korea: Clinical Features, Treatment, and Prognostic Factors. Korean Journal of Internal Medicine, 2010, 25, 227.	0.7	8
707	Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy. Korean Journal of Internal Medicine, 2016, 31, 560-569.	0.7	2
708	Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. Journal of Clinical and Experimental Hematopathology: JCEH, 2017, 57, 120-142.	0.3	72
709	Primary Splenic and Nodal Marginal Zone Lymphoma:. Journal of Clinical and Experimental Hematopathology: JCEH, 2005, 45, 1-14.	0.3	5
710	Different Histopathological Types of Orbital Lymphoma 16 Years after Systemic Follicular Lymphoma: Immunohistochemical and Immunogenetic Analyses of Two Cases. Journal of Clinical and Experimental Hematopathology: JCEH, 2008, 48, 17-24.	0.3	11
711	Primary mediastinal lymphomas, their morphological features and comparative evaluation. Lung India, 2017, 34, 19.	0.3	11
712	Primary hepatic extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. Journal of Pathology and Translational Medicine, 2020, 54, 340-345.	0.4	8
713	Long-Term Survival after T-cell Lymphoblastic Lymphoma Treated with One Cycle of Hyper-CVAD Regimen. Cancer Research and Treatment, 1970, 47, 115-119.	1.3	5
714	Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma. Cancer Research and Treatment, 2017, 49, 92-103.	1.3	4
715	Primary mucosa-associated lymphoid tissue lymphoma of the liver: A report of two cases and review of the literature. World Journal of Hepatology, 2017, 9, 155.	0.8	14
716	Prevalence and Implications of Bone Marrow Involvement in Patients with Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Gut and Liver, 2018, 12, 278-287.	1.4	11
717	Grading of follicular lymphoma using flow cytometry. Annals of Saudi Medicine, 2006, 26, 205-210.	0.5	6
718	T-Cell Lymphomas in South America and Europe. Revista Brasileira De Hematologia E Hemoterapia, 2011, 34, 42-47.	0.7	38
719	Time-to-treatment of diffuse large B-cell lymphoma in São Paulo. Clinics, 2014, 69, 367-371.	0.6	3
720	A Lymphoma Almost Overlooked. Cureus, 2018, 10, e2110.	0.2	1
721	Linfoma no Hodgkin. 593 autopsias en el Hospital Clínico-Quirúrgico "Hermanos Ameijeiras" 1983-2020.. Archivos De Patología, 2021, 2, 37-44.	0.1	0
722	Primary sinonasal large B cell lymphoma is as histopathologically heterogeneous as systemic large B cell lymphoma but may show subtype-specific tropism for specific sinonasal anatomic sites. Journal of Hematopathology, 2021, 14, 269.	0.2	0

#	ARTICLE	IF	CITATIONS
724	A case of malt lymphoma of the lung.. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.0	0
725	A Resected Case of the Follicular Lymphoma of the Duodenum.. Japanese Journal of Gastroenterological Surgery, 2002, 35, 1497-1501.	0.0	0
726	Primary Follicular Lymphoma in the Submandibular Lymph Node accompanied by a Chronic Sialadenitis of the Submandibular gland: A case report. Oral Medicine & Pathology, 2004, 9, 155-161.	0.3	0
727	A case of MALT lymphoma of the larynx. Koutou (the LARYNX JAPAN), 2004, 16, 135-138.	0.1	2
728	A Case of Splenic Marginal Zone Lymphoma Diagnosed after Splenectomy for ITP. Japanese Journal of Gastroenterological Surgery, 2005, 38, 1816-1820.	0.0	1
729	Diagnoses of Canine and Feline Malignant Lymphomas Using the New WHO Classification. Nippon Juishikai Zasshi Journal of the Japan Veterinary Medical Association, 2008, 61, 543-548.	0.0	0
730	A resected case of pulmonary metastases from malignant lymphoma of the stomach. The Journal of the Japanese Association for Chest Surgery, 2009, 23, 630-635.	0.0	0
731	A case of small lymphocytic lymphoma arising in the palate. Nihon Koku Geka Gakkai Zasshi, 2011, 57, 501-505.	0.0	1
732	Towards Personalized Medicine in Pediatric Cancer: Genome-Wide Strategies to Investigate Cancer Risk and Response to Therapy. , 2012, , 1-19.		0
733	The Role of Hematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphomas. , 2013, , 279-293.		1
734	Angioimmunoblastic T-cell lymphoma-associated pure red cell aplasia with abdominal pain. World Journal of Clinical Oncology, 2013, 4, 75.	0.9	1
736	Primary colorectal lymphoma: computed tomography and double-contrast barium enema examination findings with histopathological correlation in 19 patients. Annals of Translational Medicine, 2019, 7, 308-308.	0.7	3
737	Important Prognostic Factors of 447 Cases of Non-Hodgkin's Lymphoma Reviewed by Hematopathologists: Proposal of Lymphoma Clinico-pathological Prognostic(LCP) Classification and LCP Schema as A Predictive Model.. The Journal of the Japanese Society of Lymphoreticular Tissue Research, 1998, 38, 41-55.	0.0	1
738	Lymphoplasmacytic lymphoma and PAX-5 gene. The Journal of the Japanese Society of Lymphoreticular Tissue Research, 1999, 39, 273-281.	0.0	0
741	Mucosa-associated lymphoid tissue (MALT) lymphoma of the small intestine. PatologÃe, 2015, .	0.1	0
742	Contrast-enhanced fluorodeoxyglucose positron emission tomography/contrast-enhanced computed tomography in mediastinal T-cell lymphoma with superior vena cava syndrome. Indian Journal of Nuclear Medicine, 2016, 31, 79.	0.1	1
743	T-Cell Lymphomas. , 2016, , 603-614.		0
744	Mantle cell lymphoma. , 2017, , 113-122.		0

#	ARTICLE	IF	CITATIONS
745	Peripheral T-cell lymphoma, not otherwise specified. <i>Journal of Family Medicine and Primary Care</i> , 2017, 6, 427.	0.3	0
746	Infiltrative Rash Secondary to Leukemic-Phase Diffuse Large B-Cell Lymphoma With t(14;18), CDKN2A and MLL Deletion. <i>Journal of Hematology (Brossard, Quebec)</i> , 2017, 6, 90-95.	0.4	0
747	Mantle cell lymphoma: Saudi Lymphoma Group's clinical practice guidelines for diagnosis, management and follow-up. <i>Saudi Journal of Medicine and Medical Sciences</i> , 2019, 7, 226.	0.3	1
748	Prognostic relevance of genetic variations in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. <i>Translational Cancer Research</i> , 2019, 8, 2485-2495.	0.4	5
749	Expression of Foxp3 and interleukin-7 receptor and clinicopathological characteristics of patients with diffuse large B-cell lymphoma. <i>Oncology Letters</i> , 2020, 19, 2755-2764.	0.8	5
750	The prognostic importance of double-expressor subgroup and AID , UNG and mismatch repair protein expressions in diffuse large B-cell lymphomas. <i>Marmara Medical Journal</i> , 0, , .	0.2	0
751	Blastoid Mantle Cell Lymphoma of the Palate: Report of a Rare Aggressive Entity and Review of the Literature. <i>Head and Neck Pathology</i> , 2022, 16, 631-642.	1.3	1
752	The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma. <i>Cancer Cell International</i> , 2021, 21, 573.	1.8	5
753	Uncommon Tumors and Uncommon Presentations of Cancer in the Breast. <i>Current Breast Cancer Reports</i> , 2021, 13, 331.	0.5	1
754	Intestinal T-cell lymphoma, NOS, presenting with sole peritoneal and mucosal lymphomatosis throughout abdominal cavity. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2020, 60, 117-120.	0.3	3
755	Unusual location of recurrent mantle cell lymphoma on fluorodeoxyglucose-positron emission tomography despite complete metabolic resolution of previous sites of disease. <i>World Journal of Nuclear Medicine</i> , 2020, 19, 277.	0.3	0
756	A case of B-cell type lymphoma coexisted in mandible and central nervous system. <i>Journal of Japanese Society of Oral Oncology</i> , 2020, 32, 45-55.	0.0	0
757	Radiotherapy alone for stage IE ocular adnexal mucosa-associated lymphoid tissue lymphomas: long-term results. <i>Radiation Oncology</i> , 2020, 15, 25.	1.2	11
758	Breast Implant-associated Anaplastic Large Cell Lymphoma Affecting a Neosubpectoral Pocket. <i>Cureus</i> , 2020, 12, e7178.	0.2	0
760	CXCR4/CD184 Immunoreactivity in T-Cell Non-Hodgkin Lymphomas With an Overall Th1- Th2+ Immunophenotype. <i>American Journal of Clinical Pathology</i> , 2003, 119, 0-0.	0.4	0
761	Enterocolic fistula associated with an intestinal lymphoma. <i>MedGenMed: Medscape General Medicine</i> , 2007, 9, 28.	0.2	3
762	A rare pediatric case of a thymic cytotoxic and lymphoblastic T/NK cell lymphoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2010, 3, 437-42.	0.5	2
763	A case of primary mucosa-associated lymphoid tissue lymphoma of the prostate. <i>Rare Tumors</i> , 2009, 1, e55.	0.3	6

#	ARTICLE	IF	CITATIONS
764	Review. Gastroenterology and Hepatology, 2007, 3, 394-5.	0.2	0
765	Subtle bone marrow involvement by large B-cell lymphoma with pronormoblast-like morphology and prominent but not exclusive sinusoidal distribution. American Journal of Blood Research, 2012, 2, 113-8.	0.6	3
767	Overexpression of IL-9 receptor in diffuse large B-cell lymphoma. International Journal of Clinical and Experimental Pathology, 2013, 6, 911-6.	0.5	18
769	C-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas. International Journal of Clinical and Experimental Pathology, 2014, 7, 5634-44.	0.5	10
770	Sino-nasal T-cell lymphoma invading the brain: A case study. Journal of Innovative Optical Health Sciences, 2014, 9, 235.	0.5	0
771	Autologous hematopoietic stem cell transplantation in chemotherapy-sensitive lymphoblastic lymphoma: treatment outcome and prognostic factor analysis. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 66-73.	0.7	7
772	EBV+ diffuse large B-cell lymphoma arising within atrial myxoma in Chinese immunocompetent patient. International Journal of Clinical and Experimental Pathology, 2015, 8, 2159-64.	0.5	7
773	Mantle cell lymphoma concurrent with T-large granular lymphocytic leukemia: report of a case and review of literature. International Journal of Clinical and Experimental Pathology, 2015, 8, 3365-9.	0.5	2
775	T-cell/Natural killer-cell neoplasms presenting as leukemia- Case series from single tertiary care center. International Journal of Hematology-Oncology and Stem Cell Research, 2016, 10, 13-20.	0.3	0
779	The First Confirmed Case of Breast Implant-Associated Anaplastic Large Cell Lymphoma in Hawai'i. Hawai'i Journal of Health & Social Welfare, 2019, 78, 338-340.	0.2	0
780	Histological type distribution and expression of nm23, VEGF, TOP2A and MUM-1 in peripheral T-cell and NK-cell lymphomas in Chinese: analysis of 313 cases. International Journal of Clinical and Experimental Pathology, 2018, 11, 5086-5093.	0.5	0
781	To Determine the Prognostic Significance of 18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scan-Derived Parameters (Total Lesion Glycolysis and Metabolic) Tj ETQq1 1 0,784314 rgBT /Overl Journal of Nuclear Medicine. 2020. 35. 100-104.	0.1	0
785	B-lymphoblastic lymphoma with renal lesions as first symptom in a child: a case report and review of literature. International Journal of Clinical and Experimental Pathology, 2020, 13, 1760-1765.	0.5	0
787	Mantle cell lymphoma presenting with lethal atraumatic splenic rupture. Autopsy and Case Reports, 2021, 11, e2021340.	0.2	2
788	Impact of the microenvironment on the pathogenesis of mucosa-associated lymphoid tissue lymphomas. World Journal of Gastrointestinal Oncology, 2022, 14, 153-162.	0.8	1
789	Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients Managed at Chinese Academic Centers in the Rituximab Era: A Real-World Study. Frontiers in Oncology, 2021, 11, 770988.	1.3	3
790	Follicular lymphoma: updates for pathologists. Journal of Pathology and Translational Medicine, 2022, 56, 1-15.	0.4	8
791	DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway. Neoplasia, 2022, 24, 50-61.	2.3	1

#	ARTICLE	IF	CITATIONS
792	The Role of Epstein-Barr Virus in Modulating Key Tumor Suppressor Genes in Associated Malignancies: Epigenetics, Transcriptional, and Post-Translational Modifications. <i>Biomolecules</i> , 2022, 12, 127.	1.8	11
793	Flow-Cytometry in the Diagnosis of Diffuse Large B-Cell Lymphoma Based on Stomach Tissue Samples: A Case Report. <i>Cureus</i> , 2022, 14, e21766.	0.2	0
794	Artificial Intelligence Analysis of Gene Expression Predicted the Overall Survival of Mantle Cell Lymphoma and a Large Pan-Cancer Series. <i>Healthcare (Switzerland)</i> , 2022, 10, 155.	1.0	19
795	High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients. <i>Cancers</i> , 2022, 14, 338.	1.7	2
796	Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma. <i>Frontiers in Immunology</i> , 2022, 13, 835103.	2.2	5
797	A case of primary mucosa-associated lymphoid tissue lymphoma of the prostate. <i>Rare Tumors</i> , 2009, 1, 169-170.	0.3	9
798	Diagnostic Interval in Extranodal Non-Hodgkin Head and Neck Lymphomas. <i>Journal of Clinical Medicine</i> , 2022, 11, 853.	1.0	1
799	Analysis of the Clinicopathologic Characteristics and Prognosis of Head and Neck Lymphoma. <i>Analytical Cellular Pathology</i> , 2022, 2022, 1-13.	0.7	2
800	Diffuse Large B Cell Lymphoma with Cutaneous and Gastrointestinal Involvement. <i>Case Reports in Gastrointestinal Medicine</i> , 2022, 2022, 1-5.	0.2	0
801	Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Cancers</i> , 2022, 14, 1005.	1.7	11
802	Ofatumumab plus HyperCVAD/HD \pm MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study. <i>Cancer</i> , 2022, 128, 1595-1604.	2.0	2
803	A Case of Angioimmunoblastic T-cell Lymphoma Hidden in Plain Sight: A Delay in Diagnosis and Management. <i>Journal of Medical Cases</i> , 2022, 13, 109-114.	0.4	0
804	T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 285-308.	2.3	58
805	Use of bronchoalveolar lavage in diagnosing angioimmunoblastic T-cell lymphoma: A case report. <i>Respirology Case Reports</i> , 2022, 10, e0924.	0.3	1
806	Follicular Lymphoma. , 0, , .		1
807	WHO classification of lymphomas. , 0, , 228-256.		0
810	Lymph nodes. , 0, , 11-77.		0
811	The pathologic diagnosis of mantle cell lymphoma. <i>Histology and Histopathology</i> , 2021, , 18351.	0.5	2

#	ARTICLE	IF	CITATIONS
816	Sino-nasal T-cell lymphoma invading the brain: A case study. Journal of Innovative Optical Health Sciences, 2014, 9, 235-235.	0.5	0
817	To determine the prognostic significance of 18-fluorodeoxyglucose positron emission tomography/computed tomography scan-derived parameters (total lesion glycolysis and metabolic) Tj ETQq1 1 0.784314 rgBT /Overload Journal of Nuclear Medicine. 2020, 35, 100.	0.1	1
818	The role of surveillance computed tomography in patients with follicular lymphoma. Therapeutic Advances in Hematology, 2022, 13, 204062072210959.	1.1	1
819	Chemotherapy is an efficient treatment in primary CNS MALT lymphoma. Journal of Neuro-Oncology, 2022, 159, 151-161.	1.4	3
820	Hematologic Malignancy: The Lymphomas. , 2023, , 529-554.		0
821	Rituximab plus cladribine versus R-CHOP in frontline management of marginal zone lymphoma in China: a propensity-score matched multicenter study. Annals of Hematology, 0, , .	0.8	0